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1 INTRODUCTION 
1.1 Gene therapy 
Although gene therapy is a relatively new research area, the first approach that went 
into clinic was in 1989, already more than 1300 clinical trials have been completed or 
are still ongoing (1). Its original intention was the correction of genetic disorders by 
delivering therapeutic genes into the target cells of patients to compensate for the 
lacking or defective genetic information. Further on, delivery of genes encoding for 
therapeutic proteins or the switching-on of gene expression are commonly performed 
methods. Nowadays this is by far not the only existing toehold. Antisense 
oligonucleotides, ribozymes and small interfering RNA are designated as “loss of 
function” approaches that aim at suppressing specific gene functions. Apart from 
providing or switching-off special genetic information, genes that are delivered from 
outside can also lead to controlled cell death or activation of prodrugs.  
In 2000 a gene therapy trial from France gained massive attention with the first report 
of successful treatment of severe combined immunodeficiency disorder (SCID) in 
children. Only 2 years later, the excitement suffered a set-back when two of the ten 
children were diagnosed with leukaemia caused by integration of the retroviral vector 
in the host genome. By 2008, 5 of approximately 25 treated children developed 
leukaemia. On one hand this points out clearly the enormous potential of this new 
and promising field of therapy, on the other hand the missing of outstanding follow up 
successes is clear evidence that gene delivery systems still need to be further 
improved.  
Gene therapy embraces numerous different therapeutic approaches with the 
ambition to prevent, treat or cure diseases. Cancer found its place in gene therapy as 
in most of the cases it is a disease with genetic alterations that finally result in genetic 
defects and unregulated cell augmentation. Due to high incidence combined with a 
high mortality of cancer diseases most of the clinical trials regarding gene therapy are 
carried out in the field of cancer research. Besides inherited or acquired diseases 
based on genetic defects, vascular and infectious diseases as well as DNA 
vaccination are topics of major interest.  
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1.1.1 Gene delivery 
Delivering genes to specific cells is a process including many obstacles. Nucleic 
acids are negatively charged, hydrophilic and large macromolecules that cannot 
penetrate through lipid membranes. Additionally they are quickly eliminated in the 
organism by nucleases, mainly before they reach their target cell. These properties 
are not very suitable for their use as therapeutics. In vivo experiments already 
showed that the intravenous application of naked DNA does not lead to high 
transfection levels. If naked DNA is injected locally it has to be in large amounts to be 
efficient. Therefore gene vectors that are useful to protect DNA and that are able to 
deliver it successfully to its target cell are examined intensely. There are many 
different gene delivery approaches existing in the viral as well in the non-viral field. 
For example cationic lipids (2) and cationic polymers (PLL, PEI) that both complex 
DNA and result in so called lipo- or polyplexes or liposomes that envelope DNA 
solutions with a lipid bilayer system or combinations of both. Further on different viral 
vectors, like adeno-, retro- or lentiviral vectors are employed. Following, two of the 
main important systems are listed that are additionally directly related to this work. 
1.1.2 Adenoviral vectors 
Most of the clinical trials carried out in gene therapy studies use viral vectors. Since 
now, they are the most efficient gene vectors as their natural setup is perfectly 
concerted to invade and infect their target cell (3; 4). Adenoviruses belong to class I 
(DNA) viruses, have an icosaedric capsid and contain a large DNA genome of 30-38 
kbp. They can infect dividing and non-dividing cells and do not cause insertion 
mutagenesis as their genome does not become integrated into the host´s DNA. 
Consequently expression of genes delivered by adenoviral vectors lasts only 
temporarily. More than 51 serotypes exist which can induce inflammatory responses 
in the host tissue which additionally reduce duration of gene expression and limit 
repeated administration.  
In order to avoid replication of therapeutically applied viruses they need to be 
specially modified. Genes for viral replication are removed and replaced by the 
therapeutic gene (5). A major problem using viral vectors for gene transfer is their 
limited capacity to incorporate the additional nucleic acids that should be 
therapeutically delivered. Besides the capacity, activation of the immune system and 
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the possibility of mutagenesis, for example caused by retro-viral vectors, through 
gene insertion into the host’s genome are severe disadvantages of viral vectors. 
Additionally, handling is delicate and the production process is complex and 
expensive. 
1.1.3 Synthetic, PEI based vectors 
Non-viral gene delivery has been considered as an alternative to the intensely 
researched viral systems and increasing interest is focused on the development of 
new non-viral gene delivery systems. Chemically defined DNA carriers offer 
enhanced biosafety compared to viral vectors. Furthermore, they offer an easier 
synthesis and production as a pharmaceutical product. They are well accessible to a 
diversity of chemical modifications whereas viruses are restricted to a proteinaceous 
composition. Synthetic vectors can either be generated protein-free or by using non-
immunogenic proteins and peptides with plasmids containing no immunostimulatory 
motifs. Accordingly, non-viral vectors are less immunogenic and therefore can be 
repeatedly applied to the patient without leading to severe immune responses (6). 
Another major advantage is that there is nearly no limitation to the size of the nucleic 
acid that can be delivered. Beside all these positive aspects the main disadvantage 
of non-viral vectors is their low efficiency regarding gene transfer and a significant 
cytotoxicity depending on the used polymer.   
Till now, the most commonly used and best examined polycation (PC) for non-viral 
gene delivery is polyethylenimine (PEI). Polyethylenimine is a linear or branched 
polymer, available at different sizes (e.g. 2, 22, 25, 750 kDa) that condenses DNA by 
electrostatic interactions. At physiological pH, PEI exhibits a high cationic charge 
density with approximately every fifth to sixth nitrogen atom being protonated (7). 
This protonation profile is slightly shifted after DNA binding. In ratios of polymer 
nitrogens to DNA phosphates that are suitable to form small and homogenous 
transfection complexes in virus-like dimensions, the resulting particles exhibit a 
positive surface charge due to an excess amount of polymer. This positive surface 
charge facilitates interaction with negatively charged cell membranes hence leading 
to improved cellular uptake. Another important characteristic property of PEI is its 
huge buffering capacity which significantly contributes to its high transfection activity. 
After uptake of the vector into the cell via endocytosis acidification of the endosome 
begins and PEI induces a massive accumulation of protons leading to a passive 
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influx of chloride-ions accompanied by water. This property is called “proton sponge 
effect” (8; 9). The increase of osmotic pressure results in swelling and finally in 
rupture of the endosomolytic vesicle thus leading to improved release of PEI and the 
genetic information.  
 
1.2 Polyethyleneglycol (PEG): a commonly used 
shielding polymer 
PEG is a basically linear, uncharged, hydrophilic and non-immunogenic polymer with 
low toxicity covering sizes ranging from 200–40000 Da. Besides, branched so called 
multiarm PEGs exist. Polyethylenglycol is a polyether with repetitive -CH2-CH2-O- 
units exhibiting hydroxy groups at the end. Before coupling, they have to be 
chemically activated with a suitable leaving group that can be displaced by 
nucleophilic attack. For example by the epsilon amino group of lysine residues, by a 
protein’s N-terminus or by the amino group of a cationic polymer. Due to its versatile 
application possibilities combined with low toxicity PEG was approved by the Food 
and Drug Administration (FDA) for use in cosmetics, foods and drugs (10). 
1.2.1 PEGylation of proteins  
PEGylation, originally defined as attachment of polyethyleneglycol to drug molecules, 
was first introduced by Davis et al. in the 1970s (11). Nowadays PEGylation of 
therapeutic peptides and proteins is a well established approach (see review. (12)). 
When PEG is covalently linked to proteins it alters their properties extensively. 
PEGylation of proteins maintains their bioactivity in vivo, increases their solubility and 
reduces antigenicity and immunogenicity. PEGylated proteins are protected against 
proteolytic degradation and show increased serum half-lives due to decreased 
efficiency of drug elimination processes such as renal excretion and opsonization 
(10). Due to reduced opsonization they are less phagocyted by natural particle 
elimination mechanisms, mainly organs of the RES (reticulo endothelial system). 
Already in 1977, Abuchowski et al. (13) examined the effect of PEGylation on 
immunogenicity and circulation time of bovine liver catalase. In one of the later 
experiments Nandini v. Katre tested the influence of PEGylation on IL-2, which was 
tested in a clinical study as an anticancer therapeutic agent and induced the 
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development of antibodies in  some of the patients (14). Nowadays a couple of 
PEGylated proteins are applied successfully in clinic such as PEG-adenosine 
deaminase, PEG-Interleukin-2 and PEG-α-Interferon. The range of molecular 
PEGylation is of course much bigger with antibodies, antigens, growth factors, 
receptors (e.g. TNFR) and blood constituents, to only name a few (10). 
1.2.2 PEGylation of adenoviruses  
As the PEGylation of proteins and peptides was a well examined and successful 
research area,  O´Riordan et al. started with the PEGylation of capsid proteins of 
adenoviruses in 1999 (15). Up to 18000 PEG molecules could be attached to the 
capsid surface of one single Ad serotype 5 (Ad5) particle. PEG molecules were 
mainly attached to hexon, fiber and penton base, the best accessible outer proteins 
of the particle as shown in figure 1. 
 
 
 
 
 
 
 
 
 
 
Figure 1) Illustration of an icosaedric adenoviral particle highlighting the most important 
capsid proteins in colour. Genetic information is packed inside the capsid. 
 
Importantly, O´Riordan et al. could demonstrate in the same experiment that core 
proteins were not PEGylated indicating that PEGylation of Ad-viruses under the 
chosen conditions does not compromise the integrity of the vector capsid. 
As the proteins of hexon, fiber and penton base are known to be the main targets for 
neutralizing antibodies, their PEGylation mask them in a way that they are protected 
from being opsonized. O´Riordan et al. could show in vitro and in vivo that PEGylated 
Penton base
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Fibre
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adenoviruses could effectively escape neutralizing anti-capsid antibodies thus 
overcoming one of the most important hurdles for Ad5 mediated gene transfer.  
The degree of PEGylation that still retains most of the Ad vectors´ biological activity 
(e.g. infectivity) was analyzed by Croyle et al. (16) by using different PEG-linkers 
(tresyl-, succinimidylester-, disulfide- or cyanuric acid- PEG). Depending on the 
linker, 70–100% of capsid protein PEGylation was achieved. Interestingly, the 
repeated application of PEGylated viruses allowed only for significant transgene 
expression when different functional PEG linkers were applied in the individual 
dosing. They assumed that due to PEGylation of the vector new antigenic epitopes 
appear that cause the production of antibodies only when applied repeatedly with 
viruses PEGylated with the same linker. 
PEGylation of Ad-viruses decreases their zeta potential from -48 mV to -16 to –27 
mV. It also stabilises virus particles at 37 and 42 °C and is helpful as a cryoprotectant 
at –20 °C. Cellular and humoral immune responses were both reduced but 
PEGylated Ad viruses only led to slightly prolonged gene expression. The reason for 
this finding might be the production of new viral proteins and/or the immunogenicity of 
the transgene product itself in the transducted cell. 
PEGylation decreased association with kupffer cells and uptake by macrophages and 
also the interaction with platelets is reduced. As the injection of non-PEGylated 
viruses led to a drop in platelet count, unchanged platelet levels found in the case of 
PEGylated viruses indicate a prevention of intravascular coagulation. 
The incomplete ablation of innate immune response, which was observed with 
PEGylated virus particles let to the idea to use these vectors in combination with 
immune suppressive drugs. PEGylated viruses together with glucocorticoids led to 
complete ablation of innate immunity.  
By genetic modification of the capsid proteins fiber, hexon, penton base and pIX it is 
possible to introduce peptide ligand motifs onto the virion´s surface. However this 
often occurs with limited success since modification can alter folding of the modified 
capsid protein and/or assembly of intact capsids. Romanczuk et al. (17) developed a 
targeting approach based on the PEGylation of Ad vectors with bifunctional PEGs. 
This approach permits the use of full-length protein ligands that are too large to be 
incorporated genetically. Lancotti et al. (18) attached fibroblast growth factor 2 
(FGF2) to PEG and used this reagent in an in vivo experiment. FGF2 decorated 
adenoviral particles showed a significantly higher transduction efficiency of tumour 
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cells as PEGylated particles did. PEGylation commonly leads to lower transduction 
compared to unmodified particles. Several research groups have demonstrated that 
PEGylation with NHS (N-hydroxy succinimidyl ester) based PEGs can efficiently 
disrupt binding to CAR (coxsackie adenovirus receptor) of such PEGylated viruses. 
Of course the degree of PEGylation plays a crucial role whether CAR can be bound 
or not. As with the NHS-PEG methods the capsid is PEGylated on many different 
proteins (hexon, penton base etc.) there are hints that ligand attachment to such a 
variety of locations might interact with the correct trafficking of vectors at the cell 
surface or inside the target cell. Kreppel et al. (19) developed a so called “geneti-
chemical” approach where they genetically modified the fibre loop by introduction of 
cystein. By PEGylation with SPA-PEG (succinimidyl propionic acid- PEG) the vector’s 
native tropism was ablated but cystein at the tip of the fibre protein was accessible for 
ligand attachment. The tip of the fibre is evolutionary designed to bind to a receptor 
and the fibre protein is the first protein shed from the particle upon cell entry and 
therefore intracellular trafficking might be unhindered when the ligand is only bound 
to the fibre tip. This is still under investigation and also the pH-sensitive PEG 
reagents described here, might be taken into consideration. It seems that in vivo, 
PEGylated viruses still have limited access to CAR. Mok et al. (20) found that the 
heparin binding motif KKTK (amino acids 91 – 94) in the fibre shaft was still 
accessible to KKTK antibody even after heavy PEGylation and that additionally the 
RGD (amino acids arginin, glycin and asparagin) -integrin binding motif in the penton 
base was partially accessible among these conditions. This might play a role in the 
transduction of liver cells. They speculated that the same forces that let the virions 
pass through the fenestrae in liver sinusoids might be responsible for bending PEG 
chains and thereby giving access to KKTK and RGD motif. PEG chain length might 
also play a role. PEG prolongs circulation time and therefore uptake possibilities, as 
intravenously administrated non-PEGylated viruses are eliminated very fast. For 
detailed information see review Kreppel et al (21). 
1.2.3 PEGylation of synthetic, PEI based vectors 
One reason for the success of positively charged PEI based gene delivery vectors is 
their membrane interaction with negatively charged heparansulfat-proteoglycans on 
the cell surface (including transmembrane syndecans), that leads to increased 
uptake compared to neutral particles (22). These beneficial in vitro effects cause 
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most of the undesired side effects after in vivo application due to unspecific 
interactions with negatively charged serum proteins, membrane proteins or with 
erythrocytes. When applying PEI based polyplexes via the bloodstream the negative 
side effect of this electrostatical interaction becomes apparent. Unspecific binding of 
positively charged PEI particles to blood components leads to subsequent elimination 
by the reticulo endothelial system and can cause clotting. Additionally, binding to 
non-target cells and tissues can lead to undesired and potentially toxic side-effects. 
Taken together this results in reduced circulation times and targeting ability (23). 
Klibanov et al. (24) reported prolonged and less hindered blood circulation for 
PEGylated liposomes in 1990. Since PEI was introduced in 1995 by the group of J.P. 
Behr as a potent gene vector (8), PEGylation of PEI based gene delivery vectors was 
only a matter of time. During extracellular transport its DNA load should be delivered 
unhampered, minimizing unspecific interactions of the positively charged polyplex 
with the biological environment. Prolonged circulation times, reduction of interactions 
and inhibition of activation of the complement system (25) can be achieved by 
shielding the polyplex with an inert PEG layer on its surface. PEG shielding of 
polyplexes leads to improved stability even after freeze-thawing cycles (26). 
Additionally PEGylation of PEI based polyplexes increases the solubility of the 
complexes. The use of plain PEI as gene vector is limited by the poor solubility of the 
DNA complexes.  Complex solutions become turbid and precipitates appear at DNA 
concentrations that are much lower as when PEI–PEG/DNA polyplexes are 
generated (27). However, surface charge shielding can lead to a significantly reduced 
gene expression activity since not only undesired interactions are reduced (27; 28).  
1.2.3.1 Pre-PEGylation 
The positive effect of polyethyleneglycol modification of drugs, peptides, proteins and 
liposomes probably gave rise to investigations concerning polymer based delivery 
systems. Wolfert et al. (29) and Toncheva et al (30) developed novel vectors for gene 
delivery by self-assembly of DNA with PLL grafted to PEG. They were able to form 
discrete particles, around 100 nm in size that successfully transfected cells. Surface 
charge and also cytotoxicity of the polyplexes were decreased due to the shielding 
effect of the PEG chains. As PEI was the more efficient gene delivery vector 
compared to PLL groups started to synthesize the first PEI-PEG copolymers with 
Erbacher (31) and Kichler (27) being one of the first in 1999 and 2002 respectively. 
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Pre-PEGylation is easy to perform as it consists of simply mixing the polymer 
containing solution to that containing the DNA by pipetting. Although it is a very easy 
and quick method to generate PEGylated particles it has to be considered that only 
approximately 20% of the used polymer is PEGylated otherwise the hydrophilic parts 
seem to hinder proper DNA condensation and particle formation (32). Figure 2) 
illustrates the process of pre-PEGylation. 
 
 
 
 
 
 
 
 
Figure 2) Schematic illustration of pre-PEGylation. Polyplexes with or without targeting ligand 
are prepared in a one step reaction by mixing plasmid DNA with polycation and polycation 
coupled to PEG or to PEG-ligand.  
 
1.2.3.2 Post-PEGylation 
Another possibility to receive PEG-shielded polyplexes is the so called post-
PEGylation approach. In this method DNA is first complexed by the polycation and 
when particles have formed, the PEG reagent is added. PEG coupling to the polyplex 
surface can for example occur via active ester- (NHS) or tresyl-activated PEGs. All of 
them form stable amide bonds on the particle surface. PEI-ligand or PEI-PEG-ligand 
can also be incorporated when particles with receptor affinity are needed. These 
ligand containing conjugates are introduced into the polyplex by the pre-PEGylation 
approach mentioned above or via post-targeting as performed by Blessing et al. (33). 
The advantage of post-PEGylation is that the step by step procedure prevents any 
undesired effect of PEG-modified polycations on the DNA condensation process (34) 
and, what can be regarded as most important, that it is not restricted to non-viral 
vectors. The major drawback of post-PEGylation is that due to 1 h PEGylation time it 
is a more time consuming procedure and that the amount of PEG on the particle 
surface is not very well defined. Figure 3) illustrates the process of post-PEGylation. 
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Figure 3) Illustration of polyplex formation via post-PEGylation. DNA is first condensed by PC 
or  PC-PEG-ligand for receptor mediated uptake. Then post-PEGylation reagent is added to the 
reaction to couple to the surface amines. 
 
1.3 Design of dynamic, bioresponsive gene vectors 
Despite considerable activity in transfecting cells, the properties of PEI need to be 
further improved. It is not sufficient to compact and protect DNA; a modern gene 
vector should fulfil a number of other requirements. These aspects can not be 
operated by one single polymer and therefore it is necessary to provide the basic 
polyplex with various functional domains. The idea is to exploit the different local 
conditions and appearances that a gene vector has to pass or interact with on its way 
to or inside the cell in a way that an increased transfection rate can be obtained. The 
most striking advantage of viral particles over non-viral gene delivery vectors is that 
they are not static but react dynamically in response to the cellular environment they 
are exposed to. Therefore barriers like the endosome or the nuclear envelope are 
overcome with high efficiency. This exploitation of local conditions inspired many 
research groups to work on more dynamic, bioresponsive synthetic gene delivery 
vectors. However, with substantial efforts in the development of new transfection 
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systems and better understanding of the barriers, transfection efficiency and targeting 
of non-viral systems have improved significantly. 
1.3.1 Application of ligands 
The introduction of targeting ligands into gene delivery vectors represented a 
denoted progress in the development of more efficient transfection systems. If such a 
modified vector reaches an area with cells expressing the corresponding receptor, its 
ligand moiety can interact specifically and receptor mediated endocytosis causes 
increased particle uptake. This kind of targeting strategy that triggers receptor-
mediated endocytosis of the DNA complexes requires the knowledge of specific 
surface receptors of different cell types. The extensive search of differences in the 
appearance of tumour and normal cells, for example in regard of surface proteins, 
already showed a lot of success. Therefore gene vectors provided with special 
targeting ligands were developed. Wu and Wu were the first who used gene vectors 
provided with a targeting ligand (35). They harnessed the knowledge of hepatocytes 
expressing special asialoglycoprotein receptors and achieved enhanced gene 
expression when they applied asialoorosomucoid modified PLL as DNA compacting 
domain compared to plain PLL polyplexes. Among the first successfully introduced 
ligands to gene transfer polyplexes were transferrin (36) and insulin (37), anti-CD3 
gene transfer complexes for T cell specific uptake (38), folate (39) and EGF (40). 
1.3.2 Enzyme mediated targeting 
Another form of side specific structural changes of non-viral vectors can occur 
through an enzyme. With detailed analysis of tumour invasion and metastasis, an 
enzyme was found that is specially expressed on tumour cells. Matrix 
metalloproteinases (MMPs) are a family of endopeptidases containing a zinc-ion at 
their catalytic site. All members of the family are able to degrade extracellular matrix. 
The proteolytic breakdown of tissue barriers seems to promote intravasation and thus 
connection to the circulation via blood vessels (41). Gene vectors were designed that 
can react specifically with this enzyme that is secreted into the extracellular space. 
Hatakeyama et al. tested an approach with multifunctional envelope-typed nano 
device (MEND; condensed DNA enveloped by lipid bilayers) where they used a PEG 
– MMP substrate peptide- lipid conjugate (42). Cleavage and transfection efficiency is 
dependent on the level of enzyme expressed in the host cell. With this approach they 
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revealed stabilized MEND whilst systemic circulation, facilitating tumour accumulation 
but upon arrival at the tumour side the secreted MMPs lead to PEG removal through 
enzymatic cleavage and therefore to higher tumour cell transfection.  
1.3.3 Incorporation of endosomolytic active peptides/proteins 
Many of the commonly used gene vectors end up entrapped in the endosome as 
they do not possess any endosomolytic properties themselves and therefore efficient 
gene transfer is restricted. Escape of the entrapped particle from the endosome can 
be forced by incorporation of endosomal releasing compounds such as mellitin or 
viral based peptides (for reviews see Wagner, Meyer (43; 44)).  
A series of natural membrane destabilizing agents exist, some of them belong to 
defense mechanisms, others to affection mechanisms. For example adenoviruses 
can cause endosomal rupture, rhinoviruses can form pores in membranes, and some 
bacterial proteins lead to vesicle disrupture. A variety of viral as well as synthetic 
peptides, with or without pH specifity, cause vesicle leakage by pore formation. By 
harnessing such natural mechanisms it became possible to develop more effective 
gene delivery systems. The success of membrane active substances depends on the 
underlying polymer in the individual case. When polymers without endosomal escape 
properties, like for example PLL, are combined with such membrane active 
compounds the efficiency can raise dramatically. Whereas there is only a slight 
increase when polymers, like PEI, are used that already exhibit high efficiencies by 
themselves. Plank et al. investigated the influence of different peptides on PLL/ PLL-
Tf based gene transfer. The negatively charged peptides were bound to the positively 
charged DNA complex by electrostatic interactions. Using for example the dimeric 
peptide INF3DI they could enhance gene transfer efficiency over 5000 fold compared 
to absence of peptide. INF3D contains the same 20 N-terminal amino acids as the 
hemagglutinin subunit HA-2 of influenza virus X-31 apart from two amino acids that 
were exchanged by glutamic acids to achieve a more pH specific peptide derivative. 
As a result of the pH sensitivity, the structure of the peptide is changed in acidic 
surroundings offering a site specific membrane lytic activity (45). Saito G. et al. used 
the bacterial pore forming protein listeriolysin in a gene delivery approach with 
protamine as DNA compacting domain. Endosomal cleavage of comprised disulfide 
bonds revealed the active form of the protein and led to pore formation and 
enhanced cytosolic delivery of the gene vector (46). 
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1.3.4 Reductive cleavage by high redox potential differences 
Another possibility to change the appearance of the gene vector intracellular is to 
exploit the differences in the redox potential between oxidizing extracellular 
environment and the reducing intracellular compartment of cells. These differences 
allow for transient stability of disulfide bonds during transport in plasma but enables 
environment specific cleavage intracellular (46). Knowledge of this difference led to 
synthesis of disulfide linked polymers. On the one hand, smaller polymers exhibit 
lower cytotoxicity but also lower transfection efficiency and on the other hand large 
polymers show high cytotoxicity but high transfection efficiency (47), (48), (49), (50). 
Therefore the idea came up to use large disulfide cross linked polymers for high 
transfection activity that should be degradable in the reductive environment of the 
cytosol to small fragments with lower toxicity (51; 52). Incorporated DNA can be freed 
from the polyplex due to vector unpacking, for example initiated through RNA 
exchange (53), which occurs easier when shorter polymers are used (54). The 
principle of intracellular polymer cleavage for facilitated DNA release was 
investigated by Oupicky et al. (55). They compacted DNA with a linear PLL 
derivative, containing of short lysine subunits with cystein moieties on each end that 
were coupled by disulfide bond formation. They could demonstrate intracellular 
reduction of the disulfide bonds but achieved only poor transfection efficiencies. This 
was probably due to PLL which is not offering any intrinsic endosomolytic properties. 
Based on these findings Carlisle et al. (56) developed another strategy employing the 
reversibility of disulfide bonds. They generated a PEI based gene delivery system 
with a hydrophilic coat connected to the polyplex surface by reducible disulfide 
bonds. It was shown that removing the hydrophilic surface coat of PEI polyplexes 
intracellular by disulfide cleavage increased gene transfer efficiency up to 100 fold in 
comparison to analogue particles with stable thioether linked shielding polymer.  
1.3.5 pH-sensitive shielding 
One approach to receive more dynamic and virus like particles that are able to react 
to specific changes in the microenvironment, is the synthesis of a pH-labile PEG 
shield as it is performed in this work. While PEG shielding is very advantageous for 
long systemic circulation and thus tumour accumulation, it unfortunately reduces the 
cell transfecting ability of the corresponding polyplex. Introduction of pH-sensitive 
moieties in the shielding reagent should not affect the stability of the PEG shield 
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upon systemic circulation at physiological pH. Upon acidification of the endosome the 
pH-sensitive linkage should be cleaved shedding the PEG coat and re-exposing 
again its initial positive surface charge for enhanced membrane interaction. Elicitor of 
this strategy was the poor transfection efficiency of PEGylated particles compared to 
their non-PEGylated counterparts and the fact that incorporation of targeting ligands 
for increased uptake did not restore the transfection efficiencies to values 
comparable to those achieved by unshielded particles. It suggests itself that PEG 
shielding also affects the intracellular processing of the particle. This reduction in 
gene transfer efficiency might be explained by depleted vector–cell membrane 
interactions in the endosomal vesicle due to the PEG coat of the particle that results 
in hampered endosomal release. The combination of endosomal swelling and 
positively charged particle surface might be necessary for improved release from the 
compartment (28). 
Chemical linkages that might be suitable for pH dependent hydrolytic degradation in 
endosomal/lysosomal compartments include acetals (57-59), ortho esters (60), vinyl 
ether (61) and hydrazones (28; 62; 63). Besides late endosomes also some tumour 
tissues exhibit an acidic environment that can be utilized for local PEG shield removal 
(64). 
In the present work the influence of a hydrazone bond (HZN) in a post-PEGylation 
approach was investigated. Walker et al. (28) have previously demonstrated 
successfully that hydrazone linkage in a pre-PEGylation experiment resulted in 
improved transfection efficiencies. The following scheme depicts the underlying idea 
of pH-sensitive PEGylation. Shielded and targeted polyplexes, taken up by receptor 
mediated endocytosis become deshielded upon acidification of the endosome, re-
expose their net positive surface charge and thus result in enhanced endosomal 
release and improved gene transfer efficiency. 
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Figure 4) Illustration of the transfection process by receptor mediated uptake mechanism for 
targeted and PEGylated polyplexes. Shield removal upon acidification, hypothesised 
membrane interaction and enhanced particle release are depicted. 
 
1.4 Purification of polyplexes 
An important step towards more biocompatible PEI based gene vectors was the 
development of purification methods for these polyplexes. When polyplexes with PEI 
are prepared at an N/P ratio of 6 the amount of unbound PEI is considerable high 
with 60–80% (65). From literature it is known that this amount of free PEI contributes 
to the good transfection efficiency of PEI based delivery systems but that it also 
correlates with the toxicity of these formulations, especially in vivo. Boeckle et al. (66) 
developed a purification method where unbound PEI was removed via a size 
exclusion approach resulting in reduced in vitro cytotoxicity. In 2007 Fahrmeir et al. 
(67) further developed this purification process by the use of an electrophoresis 
apparatus that allowed for purification of also bigger polyplexes including their 
PEGylated and/or their Tf-coupled PEI derivatives. By removing the free polymer the 
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N/P ratio of the remaining polyplex and the transfection efficiency decrease 
significantly. This reduction can be partially overcome by application of higher DNA 
concentrations.  
1.5 Aim of the thesis 
1.5.1 Synthesis of pH-labile post-PEGylation reagents 
The aim of this thesis was the development of a pH-sensitive post-PEGylation 
reagent that is not as restricted to polyplex shielding as pre-PEGylation approaches 
are. This new pH-labile post-PEGylation reagent can theoretically be used for 
shielding of any amine group bearing gene delivery vectors.  
As already mentioned above, PEGylation of polyplexes results in desired and 
undesired effects. On the one hand the introduction of a hydrophilic coat surrounding 
the polyplex results in longer circulation times and reduced toxicity due to less 
unspecific interactions with blood components and proteins but on the other hand 
these reduced interactions are finally responsible for lower gene transfer efficiency. 
As the introduction of targeting ligands for enhanced cellular uptake did not restore 
the transfection efficiency to values comparable to non-PEGylated particles the idea 
came up to synthesize pH-sensitive post-PEGylation reagents that allow for 
environment-sensing modulations. Upon circulation the particle is protected from 
unspecific interactions but when reaching the endosome the decrease of pH triggers 
the removal of the PEG shield presenting the positive surface charge that was hidden 
before. This allows for charge interactions with endosomal membranes and facilitates 
release of the entrapped vector (28). For closer characterisation two variants of pH-
labile shielding PEG reagents had to be synthesized namely the monofunctional 
NHS-HZN-PEG and the bifunctional OPSS-PEG-HZN-NHS. The latter provides a 
platform for PEG chain modification with a fluorescent dye to visualise deshielding of 
such Alexa-PEGylated (Alexa Fluor® 488) polyplexes among acidic conditions. 
Additionally, this pH-labile bifunctional PEG could function as a starting base for 
future post-targeting studies on polyplexes that have been PEGylated with the 
bifunctional pH-labile PEG linker. 
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1.5.2 Post-PEGylation of polyplexes and their biophysical 
characterisation 
NHS-HZN-PEG had to be tested on its shielding and deshielding ability by size and 
zeta potential measurements while the other pH-sensitive reagent, based on the 
bifunctional PEG linker, with an additional fluorescent dye molecule at one end of the 
PEG chain, should allow for observation of PEG chain cleavage from the polyplex 
surface via FCS (Flourescence Correlation Spectroscopy) measurements. For the 
latter experiment it was vitally important that particles were pure and defined. The 
dye labelled PEG reagent should provide the accessory possibility to shed light on 
the PEGylation degree and detailed composition of the final polyplex. 
1.5.3 In vitro and in vivo characterisation of novel polyplexes 
Monofunctional pH-labile PEG reagent had to be analyzed for its assignment on PEI 
based polyplexes in in vitro cell culture studies and in an in vivo tumour mouse 
model. Therefore PEI based polyplexes with or without targeting ligand had to be 
shielded with appropriate amounts of the novel shielding reagent and afterwards the 
resulting gene vectors should become tested on their transfection ability and 
efficiency.  A pH-stable comparable PEG reagent had to be used as control in these 
experiments.  
Finally, PEI polyplexes with targeting ligand and stable or labile PEG shield should be 
applied intravenously into mice bearing a subcutaneous HuH7 tumour to clarify 
whether the new pH-sensitive PEG reagent is a promising candidate under in vivo 
conditions. 
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2 MATERIALS AND METHODS 
2.1 Chemicals and reagents 
Dimethylformamide (DMF) and 1-amino-3,3-diethoxypropane (ADEP) were 
purchased from Sigma-Aldrich (Steinheim, Germany), ethanolamine, cysteamine and 
picrylsulfonic acid (trinitrobenzenesulfonic acid TNBS) from Fluka were also acquired 
over Sigma-Aldrich. Methoxypoly-(ethyleneglycol)-butyraldehyde (ALD-PEG; 20 kDa) 
and mPEG-propionic acid succinimidyl ester (mPEG-SPA 20 kDa) were purchased 
from Nektar Therapeutics (Birmingham, AL). These reagents are now available from 
Sunbio (Orinda, CA) and Chemos GmbH (Regenstauf, Germany). α-
succinimidylester-ω-2-pyridyldisulfid polyethylene glycol (OPSS-PEG; 10 kDa) was 
synthesised from IRIS Biotech GmbH (Marktredwitz, Germany). Succinimidyl-6-
hydraziniumnicotinatehydrocloride (SHNH) was purchased from Solulink Inc. (San 
Diego, CA). Benzyloxybenzaldehyde polystyrene beads (Novabiochem) were 
obtained from Merck Biosciences AG (Läufelfingen, Schweiz) and L-glycine from 
Fisher Scientific GmbH (Nidderau, Germany). Cell culture media, antibiotics, 
trypsin/EDTA solution and fetal calf serum (FCS) was purchased from Life 
Technologies, Alexa Fluor® 488 carboxylic acid, succinimidyl ester from Molecular 
probes, all by Invitrogen (Karlsruhe, Germany).  
2.2 Polyethylenimine 
Branched PEI with an average molecular weight of 25 kDa (BPEI) was purchased 
from Sigma-Aldrich (Steinheim, Germany). LPEI with an average molecular weight of 
22 kDa was synthesized by acid-catalysed deprotection of poly(2-ethyl-2-oxazoline) 
(50 kDa, Aldrich, Munich, Germany) in analogous form as described (68). It is also 
commercially available from Polyplus (Strassbourg, France). Polymers were 
dissolved in water and then neutralized with HCl. For purification they were applied 
on a gelfiltration column with Sephadex G-25 superfine using 20 mM HEPES with 
0.25 M NaCl at pH 7.4. For polyplex preparation LPEI was used as 1 mg/ml stock 
solution in HBG and BPEI in HBS 0.5x. 
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2.3 mEGF-PEG-BPEI 
Epidermal growth factor (EGF) from PeproTech, Inc. (NJ, USA) linked with BPEI by a 
heterobifunctional 3.4 kDa PEG derivative was synthesized as described previously 
(40) with a molar ratio of EGF to BPEI of approximately 1:1. 
2.4 Plasmid DNA 
For in vitro cell culture experiments plasmid pCMVLuc (Photinus pyralis luciferase 
under control of the CMV enhancer/promoter) described in Plank et al. (69) was 
purified with the EndoFree Plasmid Kit from Qiagen (Hilden, Germany). For in vivo 
experiments endotoxin free pCMVLuc was purchased from PlasmidFactory 
(PlasmidFactory GmbH & Co. KG, Bielefeld, Germany). For polyplex preparation with 
LPEI 1mg/ml stock solution in HBG and with BPEI in HBS 0.5x was used. 
2.5 Syntheses of PEGylation reagents and PEG 
conjugate 
2.5.1 Synthesis of monofunctional N-hydroxysuccinimidyl-hydrazone- 
poly(ethylene) glycol (NHS-HZN-PEG) 
Monofunctional hydrazone-mediated reagent (NHS-HZN-PEG) was formed with a 
high molecular weight PEG (20 kDa). ALD-PEG 20 kDa (1 µmol) in 0.8 ml of 
anhydrous DMF was added to SHNH (4 µmol) in 0.2 ml anhydrous DMF. The 
reaction was mixed for 2 h at room temperature under argon in a 2 ml reaction tube. 
For removal of unreacted SHNH the reaction mixture was subsequently incubated at 
room temperature for 4 h on a rotation wheel with 0.4 mmol benzyloxybenzaldehyde 
polystyrene-beads, pre-soaked for 20 minutes in DMF, offering a 100 fold molar 
excess of bead-aldehyde groups over SHNH. After removal of the beads by 
centrifugation the reagent was tested on absence of SHNH and on ester activity by 
TNBS assay and was then subsequently stored frozen at –80 °C in aliquots of 100 µl.  
2.5.1.1 Reaction efficiency between aldehyde and SHNH 
The efficiency of the reaction between PEG-aldehyde and SHNH was analysed by 
determination of the decrease of NH2 groups. 0.5 µmol PEG-CHO dissolved in 0.4 ml 
DMF were reacted with 2 µmol of SHNH dissolved in 0.1 ml of anhydrous DMF. The 
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second approach contained 1 µmol PEG-CHO and 0.25 µmol SHNH in 0.8 
respectively 0.2 ml of DMF. Samples were analysed via TNBS assay right after 
mixing and after 0.5, 2, 6 and 20 hours. For reagent synthesis SHNH was used in 4 
molar excess over PEG-aldehyde. 
2.5.1.2 Removal of excess SHNH 
Unreacted SHNH (applied in an excess over PEG-aldehyde) was removed by 
immobilization onto benzyloxybenzaldehyde (polystyrene-CHO) beads. 
Completeness of SHNH removal was monitored by TNBS assay on free, primary 
amino groups. To test what molar excess of bead –CHO groups was necessary for 
the complete removal of unreacted SHNH a defined amount of SHNH in DMF was 
implemented with benzyloxybenzaldehyde beads pre-soaked in DMF offering a 10, 
50, 100, 150 or 200 fold molar excess of –CHO groups over SHNH. TNBS assay was 
performed before and after incubation with polystyrene beads and the remaining 
amount of SHNH was determined. 
2.5.1.3 Ester reactivity 
Each 2 µmol of NHS-HZN-PEG and NHS-PEG were separately dissolved in 1 ml of 
DMF and were implemented with equimolar amounts of ethanolamine. After one hour 
incubation time at room temperature the degree of conversion was determined by 
monitoring the remaining amount of primary amines by TNBS assay.  
2.5.2 Synthesis and stability of BPEI-(HZN)-PEG 
On the basis of an experiment from Kursa et al. (32) a gel-filtered solution of BPEI-
HCl (0.12 µmol), at pH 6.0 in 1 ml of 0.25 M NaCl, was mixed with 0.36 µmol of NHS-
PEG or NHS-HZN-PEG  dissolved in anhydrous DMF. The pH of the solution was 
adjusted to 7.2. After 1 h, 2 M NaCl solution was added to the batch to give a final 
concentration of 0.5 M NaCl and a total volume of 2 ml. The reaction mixture was 
loaded on a cation-exchange column (Macro-prep High S; HR 10/10, BioRad, 
München, Germany) and fractionated with a salt gradient (see 2.21). Fractions were 
collected and analysed via PEG- (see 2.17) and TNBS-assay (see 2.18). Fractions 
containing the conjugate PEI-(HZN)-PEG (positive for PEI and PEG) were pooled 
and PEI content was determined. The pooled fractions were divided into aliquots 
containing 30 nmol PEI and were subsequently frozen. For analysis of the stability of 
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these conjugates they were thawed and reapplied onto the column immediately or 
after 1 h respectively 4 h of incubation at 37 °C.  
2.5.3 Synthesis of N-hydroxysuccinimidyl-hydrazone- poly(ethylene) 
glycol pyridyldisulfide (NHS-HZN-PEG-OPSS) 
 To 1 ml OPSS-PEG-NHS 10 kDa (1 µmol) in anhydrous DMF, 5 µmol of ADEP were 
added. The reaction was mixed under argon in a 1 ml tube for 2 h at room 
temperature. Excess ADEP was removed as described in 2.5.3.1. The pool 
containing the PEG reagent was acidified with 1 M HCl to a 0.1 M solution to 
deprotect the acetal whilst incubating for 1 h at room temperature. To receive an 
anhydrous sample and for HCl removal the product was freeze dried over night. The 
product was dissolved in 0.8 ml DMF. To 0.8 ml sample containing 1 µmol of OPPS-
PEG-aldehyde, 0.2 ml SHNH solution (4 µmoles in DMF) were added and mixed 
under argon. Reagents were allowed to react for 2 h at room temperature and were 
subsequently incubated with DMF soaked benzyloxybenzaldehyde polystyrene-
beads to remove unreacted SHNH. Therefore a 100 fold molar excess of bead- 
aldehyde groups over SHNH was applied. 4 h later the beads were removed by 
centrifugation and the reagent was tested on absence of SHNH and on ester activity 
by TNBS assay (similar as described under 2.5.1.2&3) and was subsequently frozen 
at –80 °C. 
2.5.3.1 Removal of excess ADEP 
Excess of unreacted ADEP was removed by gelfiltration on a 10/30 Sephadex G25 
column. The sample was diluted with water to a final volume of 2 ml and the run was 
performed in water as well. Fractions were tested on PEG content via PEG-assay 
and positive fractions were pooled. For determination of reaction efficiency fractions 
were additionally tested via TNBS assay on ADEP. A preliminary run with plain ADEP 
revealed a recovery of approximately 100% and thus the pool of retained ADEP 
allows for calculation of the coupling ratio. 
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2.5.4 Synthesis of Alexa488-disulfide poly(ethylene) glycol (hydrazone-) 
N-hydroxysuccinimidylester (Alexa-SS-PEG-(HZN)-NHS) 
Alexa488-succinimidylester was mixed in DMF under argon and light protected for    
1 h in a 1:1 ratio with cysteamine to form Alexa488-(2-mercaptoethyl)-amide. The 
efficiency of this reaction was determined via TNBS assay detecting the free amines 
of unreacted cysteamine. For synthesis of the Alexa labelled PEG-reagents, the pH-
sensitive or the stable one, reagents were mixed with Alexa488-(2-mercaptoethyl)-
amide in DMF with an excess of PEG over cysteamine modified Alexa488-
succinimidylester of 25%. Progress of the reaction could be monitored by measuring 
the release of 2-pyridinethione at 343 nm (see 2.19). Afterwards the conjugate was 
snap frozen and stored at –80 °C. 
2.6 Formation of polyplexes 
DNA complexes were prepared by first diluting and mixing unmodified polycation 
(PC) in 0.5x HBS (10 mM HEPES pH 7.4, 75 mM NaCl)  for BPEI or HBG (20 mM 
HEPES pH 7.4, 5% glucose) for LPEI. When particles with receptor mediated uptake 
capability were required polyplexes were prepared by first diluting and mixing EGF-
PEG-BPEI with free PEI at a (w/w) ratio of 1 to 9. The PC buffer solution was rapidly 
mixed with plasmid DNA, diluted in either 0.5x HBS pH 7.4 (BPEI) or HBG pH 7.4 
(LPEI) by pipetting. In standard PEI polyplexes, a molar ratio of PEI nitrogen atoms to 
DNA phosphates (N/P) of 6 was applied. Complexes were incubated for 20 min at 
room temperature before indicated molar (PEG/PEI) equivalents of the activated 
ester PEG reagents were added in DMF. After 1 h, unreacted reagent was quenched 
by adding equal molar amounts of an aqueous solution of glycine (1 µmol/ml) in 
regard to PEG. Afterwards particles were ready to be used. Final DNA concentration 
for in vitro application was 20 µg/ml and 200 µg/ml for in vivo experiments. 
2.7 Particle size and zeta potential 
Particle size of DNA complexes was measured by laser-light scattering using a 
Malvern Zeta Sizer 3000 HS and/or a Zeta Sizer Nano series ZEN 3600 (Malvern 
Instruments, Worcestershire, UK). For particle sizing complexes were formed at    
100 µg/ml and were allowed to stand for 20 minutes. Before measuring they were 
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diluted to a final DNA concentration of 10 µg/ml (total volume 1 ml) with the buffer 
they were prepared in. BPEI particles were formed in 0,5x HBS whereas LPEI 
particles were formed in HBG. For estimation of surface charge, transfection 
complexes were diluted five fold in 1 mM NaCl to give a final DNA concentration of   
2 µg/ml and zeta potential was measured as previously described (15). Average 
conductivity observed in these measurements was approximately 1 mS. 
2.7.1 Shielding ability of PEG reagents 
Therefore different polyplexes (LPEI/BPEI, +/- EGF) were prepared as described in 
2.6. These complexes were incubated for 20 min at room temperature before 
increasing amounts of molar equivalents (PEG/PEI) of the activated ester PEG 
reagents (NHS-HZN-PEG or NHS-PEG of 2 and 20 kDa or OPSS-PEG-HZN-NHS or 
OPSS-PEG-NHS of 10 kDa) were added in DMF. After 1 h incubation time at room 
temperature, corresponding size and zeta potential was measured. 
2.7.2 Deshielding ability of NHS-HZN-PEG shielded particles 
The hydrolysis of the labile HZN-bond was monitored indirectly by zeta potential and 
size measurements of polyplexes PEGylated with NHS-HZN-PEG 20 kDa. Particles 
were prepared as described above. 100 µl of the PEGylated particles (100 µg/ml 
DNA, stable or labile PEG shielded with 30 fold molar excess over BPEI and 150 fold 
over LPEI) were then incubated with either 0.9 ml sodium acetate buffer pH 5.0 (20 
mM NaOAc buffer and 75 mM NaCl ) or 0.9 ml HBS  0.5x at pH 7.4 and 37°C. Size 
and corresponding zeta potential were measured after 0.5, 1, 2 and 4 h. T0 indicates 
zeta potential of particles measured in the buffer they were prepared in right after 1 h 
of PEGylation time. 
2.8 Cell culture 
HuH7 hepatocellular carcinoma cells (JCRB 0403; Tokyo, Japan) and Renca-EGFR 
mouse renal carcinoma cells (stably transfected with pLTR-EGFR and pSV2neo 
kindly provided by Winfried Wels, Georg-Speyer-Haus, Frankfurt am Main Germany) 
were grown at 37 °C in a 5% CO2 humidified atmosphere. HuH7 cells were grown in 
DMEM high glucose/F12 medium and Renca-EGFR cells in RPMI 1640 with 
Glutamax I both media supplemented with 10% FCS.  
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2.9 Gene expression in vitro 
For transfection experiments HuH7 and Renca-EGFR cells were seeded in 96 well 
plates with 1x104 respectively 7x103 cells per well 24 h prior to transfection. During 
transfection and for the following incubation time before analysis, 100 U/ml penicillin 
and 100 µg/ml streptomycin (Invitrogen GmbH) were present in the medium. 
Transfection complexes with 200 ng of pCMVLuc plasmid DNA were added per well 
of cells. After 4 h incubation at 37 °C, transfection medium was replaced by fresh 
culture medium. Luciferase gene expression was measured after 24 h.  
2.10 Luciferase reporter gene expression 
Transfection complexes containing 200 ng DNA (pCMVLuc) were added to the cells 
in 100 µl fresh culture medium containing 10% FCS in a 96 well plate. Complex 
containing medium was removed 4 h after transfection and 200 µl of fresh medium 
were added. After 24 h cell culture medium was removed and cells were washed 
once with phosphate-buffered saline (PBS) and were subsequently lyzed with 50 µl 
of reporter lysis buffer (Promega, Mannheim, Germany). Detection of luciferase 
activity was performed with a luminometer (Lumat LB9507, Berthold, Bad Wildbad, 
Germany) and luciferase activity was determined as described by Ogris et al. (70). 
Values are given as relative light units (RLU) and represent luciferase activity per 
1x104 cells as mean + standard deviations of at least triplicates. Two ng of 
recombinant luciferase (Promega, Mannheim, Germany) correspond to 107 light 
units.  
2.11 Cell viability assay (MTT assay) 
In parallel to transfection experiments, metabolic activity was determined using a 3-
(4.5-Dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) reduction assay. 
Cells were seeded in 96 well plates and treated with DNA-polyplexes and/or with 
additional used agents such as glycine or DMF in indicated amounts. After 24 h 10 µl 
of a 5 mg/ml MTT solution in sterile PBS were added to each well and the plate 
incubated at 37 °C. After 2 h, medium was removed and the samples were frozen at  
-80 °C for at least 1 h.  After thawing 100 µl DMSO were added and samples were 
incubated at 37 °C for at least 30 min under constant shaking. Optical absorbance 
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was measured at 590 nm (reference wavelength 630 nm) using a micro plate reader 
and cell viability was expressed as percentage relative to untreated control cells. 
2.12 Gene expression in vivo  
SCID mice (8 weeks of age, male and female) were housed in individually vented 
cages under specific pathogen-free conditions; food and water were provided ad 
libitum. They were inoculated subcutaneously in the flank with 5x106 HuH7 cells in 
100 µl PBS as described (40). When tumours reached a size of 6-10 mm polyplex 
formulation were prepared and injected intravenously. Most of the DMF in PEG 
reagents was removed by vacuum centrifugation before the polyplexes were added 
directly onto the pellet containing the appropriate amount of shielding reagent. After  
1 h reaction time, size and corresponding zeta potential were controlled. Particles 
containing 50 µg pCMVLuc per 20 g body weight with a concentration of 0.2 mg/ml 
DNA in HBS 0.5x (BPEI) or HBG (LPEI) were injected into the tail vein. 48 h after 
injection animals were sacrificed and indicated tissues were resected and stored at    
-80 °C. Tissues were homogenized in 1x Promega lysis buffer, pH 7.5, using an IKA-
Ultra-Turrax. Samples were centrifuged at 4 °C and luciferase activity of the tissue 
lysates was determined as described above. Luciferase background (approximately 
200 RLU) was subtracted from each value and transfection efficiency was expressed 
as RLU per organ (mean +/- SD, n=3). All animal procedures were approved and 
controlled by the local ethics committee and carried out according to the guidelines of 
the German law of protection of animal life. 
2.13 Purification of Alexa-SS-PEG-(HZN)-NHS for FCS 
measurement and determination of Alexa:PEG ratio 
Reagents stored in DMF were diluted 1:10 in running buffer (20 mM HEPES/ 0.5 M 
NaCl) and were allowed to abreact for 30 minutes before they were injected onto a 
10/30 column filled with Sephadex G25 column material. Fractions were analysed 
spectrometrically at 488 nm and via PEG assay. Distribution of Alexa488 over the 
two detected peaks can be used to calculate the PEG:Alexa ratio via Beer Lambert´s 
law with ε488 = 71000 l*mol-1*cm-1. 
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2.14 Preparation of stable and labile Alexa488-PEGylated 
BPEI particles for FCS measurement 
2.14.1 Size exclusion chromatography (SEC) 
BPEI particles were prepared as described above at an N/P ratio of 6 but for this 
experiment they were prepared in HBG. For removal of unbound BPEI the particles 
were purified on Sephacryl 200 column material (Sephacryl® S 200 HR, molecular 
weight exclusion limit 250 kDa for globular proteins; Pharmacia Biotech, Uppsala, 
Sweden) in a standard-size Pasteur pipette. The tip of the pipette was provided with 
glass wool and the column material, diluted 1:1 in water was filled to a height of 
approximately 4-5 cm. Afterwards the column was equilibrated with HBG (pH 7.4) 
and pre-conditioned with 600 µg of BPEI to reduce unspecific binding of polyplexes 
and BPEI to the column material. The column was subsequently washed with HBG 
(see also (67)). 600 µl of polyplex solution (100 µg DNA/ml) were applied onto the 
column and fractions of approximately 250 µl were collected. Fractions were 
analysed for DNA content by UV measurement respectively by TNBS assay for BPEI 
content. Polyplex containing fractions were pooled and additionally analysed for their 
DNA and polymer content (DNA concentration was calculated by 1 OD260 = 50 µg/ml 
or 45 µg/ml for DNA condensed with PEI, respectively. These values have been 
calculated after comparing plain plasmid DNA solutions with standard BPEI 
polyplexes). Out of these data final N/P ratio after purification were calculated. 
The purified particles were subsequently post-PEGylated for 1 h at room temperature 
with a 30 fold molar excess of either Alexa-SS-PEG-HZN-NHS or Alexa-SS-PEG-
NHS. To obtain Alexa-PEGylated particles with a minimum of free dye an additional 
size exclusion chromatography was performed. A Waters 996 HPLC set up equipped 
with a HR 10/30 column was used. The column was packed with Sephacryl S 200 
HR material, equilibrated in HBG (pH 7.4) and pre-conditioned with 15 mg of BPEI. 
The column was washed with HEPES buffer (20 mM pH 7.4 containing 0.5 M NaCl). 
Polyplexes were filled up to the injection volume of 1 ml with as much of a 5 M NaCl 
stock solution to give a final concentration of 0.5 M salt. SEC was performed at a flow 
rate of 0.5 ml/min; fractions of 1 ml were collected and elution of DNA-polyplexes was 
monitored at 260 nm. Afterwards fractions were analyzed via PEG assay and DNA 
and Alexa content were determined by additional UV/VIS measurements. For 
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analysis of FCS experiments only the fractions up to and including the peak 
maximum were pooled.  
2.14.2 Dialysis 
For dialysis, a variety of molecules is placed into a semipermeable dialysis bag with 
pores and afterwards the sealed bag is put into a container which contains a huge 
volume of water or buffer. Small molecules can then pass through the tubing whereas 
larger molecules with dimensions significantly greater than the pore diameter cannot. 
Dialysis was performed using regenerated cellulose dialysis tubes Visking® with a 
MWCO of 14000 or ZelluTrans® V Serie with 25000 as MWCO both from Carl Roth 
GmbH & Co KG (Karlsruhe, Germany). Tubes were washed with water and allowed 
to incubate in the dialysis buffer at room temperature for about 30 min. Purified BPEI 
polyplexes were Alexa-PEGylated and afterwards diluted with HBG containing 0.5 M 
NaCl to 10 µg/ml DNA and were then filled into the tubes. Samples were dialysed 
over night under light protection against 5 litres of 20 mM HEPES pH 7.4; buffer was 
changed twice. Alexa and PEG content were analysed before and after dialysis. 
2.14.3 Electrophoresis with ElectroPrep® System 
Electrophoresis for polyplex purification was performed using AmiKa´s ElectroPrepTM 
System (available from Harvard Apparatus, Göttingen, Germany). Amika´s Electro 
Prep® system describes a combination of dialysis and targeted movement of 
charged particles underlying a certain electric field. As sample compartment, a 1.5 ml 
Teflon chamber was used with polycarbonate membranes on each side (pore size 50 
and 100 nm). Prior to use, membranes were equilibrated in buffer solution (5 mM 
NaCl, 20 mM HEPES, pH 7.4). Alexa-PEGylated polyplexes were mixed with NaCl 
solution to obtain a final salt concentration of 0.5 M. Electrophoresis was performed 
with 200 V for 20, 30 and 60 minutes and Alexa and PEG content was determined 
before and after each run.  
2.14.4 Ultra filtration 
Vivaspin® 6 ml ultra filtration devices with 100, 300 and 1000 kDa cut-off (Sartorius 
AG, Göttingen, Germany) were used for separation of unbound PEG. BPEI 
polyplexes prepared in HBG and post-PEGylated with a 60 fold molar excess of 
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Alexa-SS-PEG were centrifuged four times at 4000 g at room temperature for 5 
minutes using a Heraeus Megafuge 1.0 R. Prior to use, ultra filtration devices were 
centrifuged once with HBG for membrane equilibration. After each centrifugation 
step, polyplex solution was re-diluted to its original volume and briefly mixed by up- 
and down pipetting in order to minimize adsorption of particles on the membrane 
surface. Filtrate and supernatant were analysed for PEG (as described in 2.17), DNA 
and Alexa (UV/VIS) content. 
2.14.5 Separation via density centrifugation 
600 µl of Alexa-PEGylated (60x molar excess) purified BPEI polyplexes (100 µg 
DNA/ml 0.5x HBS) were pipetted into Eppendorf tubes that were pre-filled with 250 µl 
of a thick dextran solution (1.5 g/ml water). Tubes were centrifuged at 4000 g for 5 
minutes at room temperature using a Sigma 2 K15 centrifuge. Afterwards 
supernatant was carefully removed and analysed for PEG content. As a washing step 
500 µl of HBG were added onto the dextran cushion and removed subsequently. 
Then, the upper dextran layer was picked up with a spatula (~100 µl) and resolved in 
HBG to a final volume of 1 ml. The obtained polyplexes were analyzed via DLS, 
PEG, Alexa and DNA content were determined as described before. 
2.14.6 Anion exchange chromatography  
A 10/30 column was packed with DEAE Sepharose TM Fast Flow and equilibrated in 
20 mM HEPES pH 7.4. Injected Alexa-PEGylated BPEI polyplexes (in 0.5 M NaCl) 
were eluted with a salt gradient starting at 30 minutes and reaching 0.5 molar salt at 
the 90 minute time point. Anion exchange chromatography was performed at a flow 
rate of 0.5 ml/min; fractions of 1 ml were collected and elution of DNA polyplexes was 
monitored at 260 nm. Afterwards fractions were analyzed via PEG assay additionally 
DNA and Alexa content were determined by UV measurement.  
2.15 Fluorescence correlation spectroscopy (FCS) 
FCS detects spontaneous intensity fluctuations resulting from fluorescently labelled 
molecules diffusing through a highly focused laser illuminated volume within a 
sample. The size of this volume is fixed by the confocal detection optics and the 
excitation profile of the focused laser beam and characterized by calibration 
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measurements against a standard of a known diffusion constant. The raw signal, the 
time dependent fluorescence intensity fluctuations, is time-autocorrelated to obtain 
dynamic information on the fluorescently labelled molecules. For Brownian diffusion 
of one identical species of particles, the autocorrelation function is given by: 
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With N representing the number of particles in the illuminated volume and  
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the structure parameter, the ratio of axial to radial dimensions of the focused laser 
beam which is a measure for the dimension of the focal volume. The diffusion time τD 
of a particle through the illuminated focal volume with radius rxy is related to the 
translational diffusion coefficient D by: 
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Additional intensity fluctuations can occur resulting from intramolecular processes like 
transitions to triplet states. If these processes are well separated in the time domain 
the autocorrelation function can be written as 
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where Ttriplett denotes the triplett fraction and τ triplett the characteristic triplett decay 
time. 
A standard FCS setup from Carl Zeiss (Jena, Germany) was used including a 
ConfoCor2 module and an Axiovert200 microscope with a Zeiss C-Apochromat (40x, 
NA 1,2) water immersion objective. The 488 nm line of an Argon laser was utilized for 
fluorescent excitation. Emission light was split by a dichroic mirror and was collected 
by an Avalanche Photodiode (APD) with a 505-530 nm filter and a pinhole of 78 µm.  
Purified BPEI polyplexes N/P = 6 were post-PEGylated with either the stable or the 
labile Alexa-PEG conjugate.  To study the cleavage of PEG chains from polyplexes 
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by FCS, purified Alexa-PEGylated polyplexes were preincubated at pH 7.4 or 5.0 for 
4 h at 37 °C in the dark, and FCS measurements were performed at room 
temperature as described in Meyer et al (71). Samples were pipetted directly into 
eight-well Lab-Tek chambers (Nalge Nunc International, Rochester, NY). 
Determination of the focal volume was established via calibration against an aqueous 
solution of 10 nM Alexa488-SH before each data acquisition. For each sample 10 
measurements with sampling time of 30 s were performed. The measured 
autocorrelation curves were fitted (Zeiss ConfoCor2 software package) with equation 
(3) providing the diffusion time τD. 
 
 
 
 
 
 
 
 
 
 
Figure 4) Schematic illustration of the instrumental set up of FCS experiments. Excitation light 
passes through the tiny sample volume where existing fluorescent molecules are excited and 
their emitted light is analysed by a detector. 
 
2.16 Determination of PEGylation degree 
Alexa-PEG-NHS 10 kDa was applied in a 30 molar excess over plain BPEI polymer. 
1.4 nmol BPEI in 100 µl HBG were reacted with 42 nmol Alexa-SS-PEG-NHS in 50 µl 
DMF. After 1 h the volume was filled up to 1 ml with salt to reach a final concentration 
of 1.5 M NaCl. 
When Alexa-SS-PEG-NHS was coupled to BPEI polyplexes, these particles were 
purified in advance as described under 2.14.1. Purified polyplexes containing 1.6 
nmol BPEI were post-PEGylated adjacent with 48 nmoles of dye labelled PEG. After 
1 h PEGylation time NaCl was added to the sample batch to reach a final 
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concentration of 1.5 M salt. Dissociation of polyplexes was followed via size 
measurements. Both Alexa-PEGylated polymer and Alexa-PEGylated polymer 
originally bound in a DNA complex were applied onto a cation exchange 
chromatography column (see 2.21). Eluted fractions were analyzed for BPEI by 
TNBS assay, for Alexa by VIS absorbance, for DNA by UV absorbance (both at 
Genesys 10-S spectrophotometer, Thermo Spectronic, Rochester, USA) and for PEG 
via PEG assay. The ratio dye to PEG of the applied Alexa-PEG conjugate was 
determined in advance as described in 2.13. 
2.17 PEG assay 
PEG was determined via complex formation with Ba2+ and iodine, which can be 
measured at 590 nm. Barium chloride solution was prepared by dissolving BaCl2 in 
0.1 M HCl to form a 5% (w/v) solution. Iodine solution was prepared by dissolving 
1.27 g iodine in 100 ml water containing 2 g of potassium iodide (72). The reaction is 
dependent on the concentration of the solutions. First a red charge transfer complex 
arises with triiodide ions that turns gradually into a nearly water insoluble iodine 
complex. Performing this assay with a PEG stock solution from 0 to 75 µg/ml (same 
buffer as samples) reveals a standard curve that allows for comparison with the 
unknown samples. Absorbance at 590 nm was measured using a microplate reader 
(Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). 
2.18 TNBS assay 
Concentration of reagents containing primary amines was measured by 
trinitrobenzenesulfonic acid (TNBS) assay as described in (73). 
Standard amine solutions with a known amount of reagent and the test solutions 
containing unknown amounts of the primary amine derivative were serially diluted in 
duplicates with 0.1 M sodium tetraborate to give a final volume of 100 µl in a 96 well 
plate. Concentrations of approximately 17.5 to 210 nmol/ml amine reagent were 
achieved and then 2.5 µl of TNBS (75 nmol) in water were added to each well. After 
5-20 minutes incubation time at room temperature (depending on the strength of the 
developed colour) the absorption was measured at 405 nm using a microplate 
reader.  
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2.19 DTT cleavage assay 
To determine the efficiency of the reaction between OPSS-PEG-(HZN)-NHS and 
Alexa-SH in DMF a DTT cleavage assay was employed. By implementation with 
disulfide bond containing pyridyldithio molecules, DTT provokes the release of 2-
pyridinethione. Measuring this chromophore at 343 nm the process of the reaction 
can be determined quantitatively. In this present experiment the absorbance of the 
dye molecule at the indicated wavelength has to be taken into account before the 
data can be calculated correctly. 100 µl of a 25 µmol/ml DTT solution in water served 
as blank. To this, 40 µl of sample were pipetted, mixed thoroughly and subsequently 
values were read off when no more increase in absorbance was detectable. 
Calculation via Lambert Beer with ε = 8080 l*mol-1*cm-1. 
2.20 Ellman´s assay 
This assay is used to quantitatively determine the amount of free thiol groups in 
chemical samples. 0.4 mg Ellman´s reagent 5,5´-Dithio-bis(2-nitro-benzoic acid) 
(DTNB) dissolved in 1 ml of the corresponding Ellman´s buffer (0.2 M Na2HPO4 with 
1 mM EDTA at pH 8.0) were used as stock solution. For VIS measurement Ellman´s 
stock diluted 1:10 in Ellman´s buffer was taken as blank. Samples were mixed with 
buffer and 10% (v/v) of the stock solution. After 20 minutes the solutions were 
measured at 412 nm and concentration of –SH group calculated via Beer Lambert’s 
law with ε = 13600 -1*cm-1. 
2.21 Cation exchange chromatography  
Cation exchange chromatography was performed on a HR 10/10 column (BioRad 
Munich, Germany) packed with Macro-prep High S.  
For the experiment described in 2.5.2 BPEI-PEG conjugates were applied to the 
cation-exchange column, which was equilibrated in 20 mM HEPES buffer pH 7.4 with 
0.5 M NaCl.  For analysis of the samples the following program was applied: after 5 
minutes, salt concentration was increased with a linear gradient from 0.5 M to 3 M 
NaCl at 15 min where it maintained isocratic for another 15 minutes. Flow rate was 1 
ml/min.  
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For the experiment described in 2.16 the set up of the program was slightly different. 
The cation-exchange column was also equilibrated in 20 mM HEPES buffer pH 7.4 
with 0.5 M NaCl but the final run was with 0.5 ml/min flow rate and a gradient starting 
from 10 minutes reaching 3 M salt at 30 minutes, remaining there until 65 minutes.  
2.22 Statistics 
Where indicated, one-way analysis of variance (ANOVA) was conducted. A p value 
of less than 0.05 was considered to be significant. Duncan test was used as a post-
hoc method. As statistical software package, WinSTAT® 2003 for Excel (R. Fitch 
Software) was used. 
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3 RESULTS 
3.1 Monofunctional PEG reagents 
3.1.1 Synthesis of the post-PEGylation reagent N-hydroxysuccinimidyl-
hydrazone poly(ethylene) glycol (NHS-HZN-PEG)  
N-hydroxylsuccinimidyl-hydrazone-PEG (NHS-HZN-PEG) was synthesized via 
conjugation of the hydrazine residues of succinimidyl 6-hydraziniumnicotinate 
(SHNH) to the ω-aldehyde group of a 2 or 20 kDa PEG (Figure 5(A)). The reaction 
was performed water free in DMF under argon to minimise hydrolysis of the active 
ester. Since SHNH was applied in a 4 fold molar excess over PEG-aldehyde, 
unreacted compounds were removed afterwards. For this purpose a solid-phase 
approach was used by immobilization of non-reacted SHNH onto 
benzyloxybenzaldehyde (polystyrene-CHO) beads. After 4 h incubation the beads 
were centrifuged by a quick spin and the reagent obtained in the supernatant was 
tested on completeness of SHNH removal by TNBS assay for detection of free, 
primary amino groups. No more SHNH was detectable after incubation with the solid 
phase approach. As control for direct comparison the stable PEG reagent mPEG-
SPA (methoxypoly(ethyleneglycol) succinimdyl propionic acid Figure 5(B)) was 
applied next to the pH sensitive reagent in biophysical and biological characterisation 
experiments. 
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Figure 5 (A) Schematic illustration of the synthesis of monofunctional post- PEGylation reagent 
NHS-HZN-PEG (2 or 20 kDa). 4 µmol of SHNH were reacted with 1 µmol of PEG aldehyde in 
anhydrous DMF. Excess SHNH was removed by incubation with polystyrene –CHO beads. 
 
 
 
 
 
Figure 5 (B) Stable control mPEG-SPA (2 or 20 kDa) 
 
3.1.1.1 Reaction efficiency between the aldehyde and SHNH 
The efficiency of the reaction between PEG-aldehyde and SHNH was determined by 
the decrease of NH2-groups of SHNH that was detected by reaction with TNBS and 
measurement of the absorbance at 405 nm after 5 minutes. The reaction was found 
to proceed very fast as measurement right after compound mixing (0), already 
showed a pronounced decrease in SHNH amino groups. When SHNH was used in a 
4 fold molar excess over aldehyde 75% of the originally applied SHNH remained. 
When PEG-CHO was used in a 4 fold molar excess over SHNH, no more SHNH was 
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detectable after 2 h. Both reactions showed a reaction efficiency of 100% and 
completeness of reaction after 2 h. 
 
 
 
 
 
 
 
 
 
 
Figure 6) Estimation of reaction time between the hydrazine group of SHNH and the PEG 
aldehyde group. SHNH used in 4 fold molar excess over PEG aldehyde (black bars) or PEG 
used in 4 molar excess over SHNH (dotted bars). Reaction was carried out in DMF. Horizontal 
line at 75%. 
 
3.1.1.2 Removal of excess SHNH 
No TNBS-reactive SHNH was detectable for the 50 fold excess of bead aldehyde 
groups over SHNH already after 2 h incubation at room temperature with the solid 
phase approach. For reagent synthesis a 100 fold excess and 4 h incubation time at 
room temperature were chosen. In an earlier attempt formyl-polystyrene beads were 
shrink-wrapped into polypropylene foil that served as a semi-permeable membrane 
and were added to the reaction mixture in order to remove the excess of SHNH. This 
so called “teabag method” did not allow for sufficient removal of excess SHNH even 
after over night incubation. 
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Figure 7) Removal of excess SHNH. DMF containing SHNH was incubated with different 
amounts of –CHO bearing polystyrene beads in water free DMF. With 10 (black dots), 50 (grey), 
100 (stripes), 150 (white dots) and 200 (white) fold excess of aldehyde groups over SHNH.  
 
3.1.1.3 Ester reactivity 
To check whether NHS-HZN-PEG owns similar ester reactivity towards amines as its 
stable counterpart NHS-PEG, both reagents were reacted with defined amounts of 
ethanolamine. The remaining amount of primary amines was determined by TNBS 
assay. With an ester reactivity in the PEG reagent of 100% almost no ethanolamine 
would be detectable after the reaction. As approximately 20% of ethanolamine 
remained unreacted both reagents exhibited an ester reactivity of > 80% and thus a 
comparable reactivity towards amines. 
 
 
 
 
 
 
 
 
Figure 8) Determination of ester reactivity of NHS-PEG  and NHS-HZN-PEG  after 
implementation with ethanolamine. PEG reagents were used in equimolar amounts and 
remaining ethanolamine was determined via TNBS assay and measurement at 405 nm. 
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3.1.2  Synthesis of the pre-PEGylation reagent BPEI-HZN-PEG 
For direct comparison of pre- and post-PEGylation analogues, control conjugates 
were synthesized. PEG-PEI shielding conjugates were generated by modifying amino 
groups of BPEI with N-hydroxysuccinimide ester derivatives of PEG 20 kDa (NHS-
PEG and NHS-HZN-PEG). Conjugates were purified by cation exchange 
chromatography and stability of the PEG modified BPEI was tested by incubation and 
re-application of the PEI-PEG conjugates onto the column. This experiment clearly 
pointed out that it is possible to form a BPEI-PEG and additionally a BPEI-HZN-PEG 
conjugate. However, following stability analysis revealed that the labile BPEI-PEG 
conjugate is only temporarily stable as it broke down already after thawing. In 
contrast the stable BPEI-PEG conjugate stayed intact also after an incubation time of 
4 h at 37 °C. Among these conditions it was not possible to form the corresponding 
pH sensitive pre-PEGylation conjugate. Thus, the post-PEGylation reagent could not 
be directly compared to its pre-PEGylation analogue. Figure 9 shows the elution 
profiles from the cation exchange chromatography. The first peak in figure 9 -1 A) 
and B) represents unbound PEG. Stable and labile BPEI-PEG conjugates show 
similar profiles initially. Reinjection of the BPEI-PEG fractions after 4 hours incubation 
at 37 °C gave a single BPEI-PEG peak for the stable conjugate and 2 peaks for the 
pH-sensitive one, indicating hydrolysis of the latter into a PEG and a BPEI-PEG 
peak. Figure 10 depicts the remaining amount of intact PEG-(HZN)-BPEI after 
different incubation times. Whereas the BPEI-PEG conjugate remains stable over the 
whole period, the conjugate containing the pH-sensitive hydrazone bond became 
degraded already after thawing. 
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Figure 9)  Elutionprofile from cation exchange chromatography (Macro-Prep High S). 20 mM 
HEPES/0.5 M NaCl with linear salt gradient starting at 5 minutes and reaching 3 M salt after 15 
minutes. A) PEG-BPEI and B) PEG-HZN-BPEI. 1) Analysis direct after synthesis and 2) after 4 h 
incubation at 37 °C. PEG positive fractions were determined by PEG assay and those 
containing BPEI by TNBS assay. 
 
 
 
 
 
 
 
 
 
 
Figure 10) Remaining amount of intact conjugate in percent    after thawing and after 
incubation at 37 °C over different time periods. 
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3.1.3 Biophysical characterisation of NHS-(HZN)-PEG shielded 
polyplexes 
3.1.3.1 Shielding of polyplexes by post-PEGylation with monofunctional PEG 
reagents 
Figures 11 A) and B) show the titration curves for determination of the amount of 
post-PEGylation reagent necessary to achieve shielded polyplexes with a close to 
neutral surface charge. Therefore different polyplexes (LPEI/BPEI, +/- EGF) were 
mixed with increasing amounts of the activated ester PEG reagents NHS-HZN-PEG 
and NHS-PEG of 2 and 20 kDa. PEG content of the BPEI-PEG-EGF conjugate led to 
a partial shielding effect with the starting zeta potential of such particles being lower 
than that of untargeted polyplexes. For BPEI particles a molar excess of PEG 
molecules over PEI molecules of approximately 30 fold generated shielded particles 
with a zeta potential below 5 mV. Shielding of LPEI particles was performed in low 
salt containing buffer (HBG) to minimise salt induced aggregation. Here, results 
differed to those obtained with BPEI polyplexes, since a much higher molar ratio of 
150 fold PEG was necessary. Shielding with the 2 kDa version of the PEG reagents 
did also reduce zeta potential. However, with the applied PEG excess it was not 
possible to achieve particles with a zeta potential below 5 mV. Due to these findings, 
20 kDa PEG reagents were used in following in vitro and in vivo experiments. Only a 
small difference was observed in the molar excess required for shielding by either the 
stable or the reversible PEG reagent. This demonstrates that the activated ester of 
the synthesized pH-labile mediated PEG reagent has a similar activity towards 
amines as the commercially available stable NHS-PEG.  
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Figure 11 A) BPEI polyplexes, N/P = 6 prepared in HBS 0.5x and B) LPEI polyplexes prepared in 
HBG were post-PEGylated with increasing amounts of indicated PEG-reagents and 
corresponding zeta potential was measured. Dotted lines 2 kDa, black lines 20 kDa PEG, 
triangles – EGF (without BPEI-PEG-EGF), squares + EGF (with BPEI-PEG-EGF) 
 
Further on zeta potential and size measurements of indicated polyplexes in different 
buffers were performed to find the formulations best suitable for shielding 
experiments. Table 1) summarises the data achieved from linear or branched PEI 
polyplexes, with or without targeting ligand and the required amount of shielding 
reagent either in HBS 0.5x or in HBG. LPEI polyplexes started to aggregate in salt-
containing buffer whereas BPEI polyplexes only showed a slight increase in size 
under these conditions. LPEI particles can be stabilized by PEGylation and thus the 
aggregation process can be stopped. As already mentioned, the zeta potential of 
formulations containing the targeting conjugate is significantly reduced compared to 
formulations without such modification. After PEGylation with indicated amounts of 
shielding polymer zeta potential is reduced to values near neutral. For in vitro and in 
vivo experiments BPEI polyplexes were prepared in HBS 0.5x whereas LPEI 
polyplexes were prepared in HBG to minimize salt induced aggregation. 
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Table 1) Size and zeta potential of indicated polyplexes prepared in different buffers. Values of 
at least triplicates +/- standard deviation are shown. For PEGylated formulations size and 
corresponding zeta potential were measured after 1 h PEGylation time. A) polyplexes prepared 
and measured in HBG and B) in HBS 0.5x (only PEGylated LPEI polyplexes were prepared in 
HBG before being transferred into HBS 0.5x) 
 
3.1.3.2  Deshielding of NHS-HZN-PEG shielded particles at pH 5.0 
Stability of PEG shielded polyplexes was determined by zeta potential with (12 A) or 
without (12 B) targeting ligand or by size measurements (12 C) over time in salt 
containing buffer at pH 7.4 or 5.0. NHS-HZN-PEG shielded BPEI polyplexes 
incubated at pH 5.0 exhibited an increase in zeta potential with time whereas at pH 
7.4 no significant change could be observed. The increase in zeta potential indicated 
removal of the PEG shield and re-exposure of the positively charged particle surface. 
As the partial shielding effect of the stable incorporated targeting conjugate 
remained, zeta potential increased to approximately 13 mV compared to ~ 30 mV for 
non-targeted polyplexes. In contrast, the zeta potential of NHS-PEG shielded 
polyplexes did not change after 4 h of incubation neither at pH 5.0 nor at pH 7.4.  
Targeted polyplexes based on BPEI remained stable in size (~ 200 nm) under both 
conditions.  In contrast, LPEI polyplexes shielded with NHS-HZN-PEG underwent 
particle aggregation in the presence of salt (particle size > 1 µm) upon de-shielding at 
pH 5.0, whereas at pH 7.4 no aggregation was observed for at least 4 h. 
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Figure 12 A) Behaviour of BPEI particles with targeting ligand BPEI-PEG-EGF stable or labile 
PEGylated with a 30 fold molar excess of NHS-HZN-PEG        or NHS-PEG         over BPEI at pH 
5.0 (black lines) and 7.4 (dotted lines). B) Same as in A) but without targeting conjugate BPEI-
PEG-EGF. Deshielding in acidic environment (pH 5.0) represented by the increase of zeta 
potential can only be seen for NHS-HZN-PEG shielded particles    . C) Size over time of targeted 
LPEI polyplexes shielded with a molar excess of NHS-HZN-PEG and NHS-PEG of 150 fold over 
LPEI. Deshielding in acidic environment (pH 5.0) is represented by the increase of size only 
detected for NHS-HZN-PEG shielded polyplexes. (Size increase and aggregation are 
independent of BPEI-PEG-EGF presence). 
 
A summary of the most important differences in appearance of LPEI and BPEI 
particles in terms of size and zeta potential in neutral or acidic environments is listed 
in Table 2). LPEI based polyplexes are slightly bigger as their BPEI based 
counterparts and change their size after deshielding in acidic surrounding due to 
aggregation, whereas BPEI polyplexes keep a constant size of approximately 200 
nm. Monitoring the zeta potential of LPEI based polyplexes results in values with high 
standard deviation due to the starting aggregation of the deshielded particles in the 
salt containing buffer. BPEI polyplexes showed increasing zeta potentials up to the 
value of non-shielded targeted particles of approximately 14 mV and 22 mV for non-
targeted particles, respectively. 
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Table 2) Size and corresponding zeta potential of stable or labile PEGylated polyplexes directly 
after 1 h PEGylation time and after 2 h incubation at 37 °C either in HBS 0.5x pH 7.4 or in 
NaOAc buffer at pH 5.0.  
 
3.1.4 Biological characterisation of NHS-(HZN)-PEG shielded 
polyplexes 
3.1.4.1 In vitro transfection 
After biophysical characterisation, the influence of the pH-sensitive PEG on levels of 
gene transfer efficiency in vitro was examined. pCMV-Luc plasmid containing 
polyplexes either based on BPEI (A) or LPEI (B) were used for transfection studies 
on HuH7 human hepatocellular (Figure 13) and Renca-EGFR mouse renal 
carcinoma cells (Figure 14). Both cell lines are known to overexpress the EGF 
receptor. After 1 h PEGylation was quenched with gycine and the formulations were 
applied to the cells in medium containing 10% FCS. After 4 h of incubation at 37 °C, 
transfection medium was replaced by fresh medium. BPEI and LPEI based particles 
showed similar transfection profiles whereas for LPEI values were considerably 
higher. For targeted polyplexes, the reversible shielded polyplexes showed a 
significantly higher gene transfer efficiency of 5- to 40 fold compared to the non-
reversible shielded polyplexes thus showing the advantage of the reversible acid-
triggered de-shielding. Standard non-reversible PEG shielding led to a decrease in 
gene transfer that has previously been shown for many of such formulations. 
182 +/- 18 2 +/- 1
169 +/- 14 22 +/- 4
213 +/- 21      3 +/- 1
211 +/- 21    14 +/- 2
180 +/- 28     5 +/- 3         172 +/- 16      2 +/- 1
180 +/- 23 4 +/- 1         183 +/- 19      2 +/- 2
197 +/- 22      5 +/- 2          206 +/- 38      4 +/- 1
202 +/- 6        4 +/- 1          205 +/- 24      3 +/- 0
BPEI 100%
+30x PEG stable 
+30x PEG labile
BPEI 90%
BPEI-PEG-EGF 10%
+30x PEG stable 
+30x PEG labile 
361 +/- 17      4 +/- 1 
< 1µm            7 +/- 5
318 +/- 13     3 +/- 2         341 +/- 32      3 +/- 2
309 +/- 23      4 +/- 1          327 +/- 17      3 +/- 2
LPEI 90%            
BPEI-PEG-EGF 10%
+150x PEG stable
+150x PEG labile 
B) pH 5.0
T2h 
size               zeta
[nm]              [mV]
A) pH 7.4
T0 T2h
size            zeta                size            zeta
[nm]           [mV]                [nm]           [mV]
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Comparing the targeting effects of PEGylated particles in combination with the acid 
triggered deshielding a synergistic effect can be observed.  
 
 
Figure 13 A) In vitro transfection efficiency in HuH7 cells of EGF targeted and non-targeted 
polyplexes post-PEGylated with 20 kDa stable or acid labile shielding reagent (30 fold molar 
excess of PEG over BPEI and 150 fold over LPEI) or without shielding reagent. Each data point 
represents the mean +/- standard deviation (n=3). Complexes were prepared at a DNA 
concentration of 20 µg/ml, N/P ratio 6. Luciferase expression of A) BPEI polyplexes mixed in 
HBS 0.5x and (B) linear LPEI core particles prepared in HBG. 
 
 
Figure 14 B) In vitro transfection efficiency in Renca-EGFR cells of EGF targeted and non-
targeted polyplexes post-PEGylated with 20 kDa stable or acid labile shielding reagent (30 fold 
molar excess of PEG over BPEI and 150 fold over LPEI) or without shielding reagent. Each data 
point represents the mean +/- standard deviation (n=3). Complexes were prepared at a DNA 
concentration of 20 µg/ml, N/P ratio 6. Luciferase expression of A) BPEI polyplexes mixed in 
HBS 0.5x and (B) LPEI core particles prepared in HBG. 
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3.1.4.2 In vitro cytotoxicity studies 
In order to exclude any toxic effects of employed agents, the metabolic activity of 
treated cells as a measure of cell viability was determined by MTT assay. As 
incorporation of PEG is known to reduce the cytotoxicity of PEI formulations these 
MTT assays concentrated on additionally utilized agents. Whilst the 4 h incubation 
time in transfection approaches cells are in direct contact with the used substances 
and therefore the assay was performed in parallel and analogue to transfection 
experiments. Figure 15 pictures cell viability of two standard transfection 
experiments. In A) transfection was performed with BPEI as basic polymer and in B) 
with LPEI. The patterned bars show indicated formulations in presence of glycine 
which was added as a quencher of PEGylation. Presence of glycine slightly altered 
cell viability with big standard deviations in all cases. MTT assay on cells treated with 
DMF (Figure 15 C) showed that higher amounts of DMF lead to a significant 
decrease of cell viability. For transfection experiments the amount of applied DMF did 
not exceed 1 µl and therefore was not influencing the cell viability to a significant 
degree. 
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Figure 15 A) and B) MTT assay of a transfection of HuH7 cells with indicated polyplex 
formulations containing 200 ng pCMV Luc DNA per 10000 cells and a molar excess of PEG over 
BPEI of 30 respectively 40 (- EGF) and 150 respectively 200 (- EGF) over LPEI. Black bars 
represent untreated control cells and patterned bars the indicated formulation in presence of 
glycine. C) Cell viability after 4 h incubation with indicated amounts of DMF. Black bar 
represents untreated control cells. All assays were performed 24 h after treatment.  
 
3.1.4.3 In vivo transfection 
As the bioreversible shielded particles were successful in vitro, they were tested in an 
in vivo model of mice bearing a subcutaneous HuH7 tumour. Therefore, acid labile- 
and stable shielded EGF-targeted LPEI and BPEI polyplexes were injected into the 
tail vein of tumour bearing SCID mice. Figure 16 shows that the bioreversible 
shielded polyplexes resulted in a more than 14 fold higher luciferase gene expression 
for LPEI (2.5 fold for BPEI) polyplexes compared to the stable shielded particles with 
a predominant gene expression found in the subcutaneous HuH7 tumour. All other 
organs showed weak luciferase expression with slightly higher values in lung and 
liver. 
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Figure 16) Luciferase expression of in vivo gene transfer into SCID mice bearing subcutaneous 
HuH7 hepatocellular carcinoma. All polyplexes contained 10% BPEI-PEG-EGF as targeting 
ligand. Polyplexes shielded either with stable NHS-PEG or labile NHS-HZN-PEG as shielding 
reagent (30 fold over BPEI, 150 fold over LPEI). LPEI polyplexes prepared in HBG and BPEI in 
HBS 0.5x.  
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3.2 Bifunctional PEG reagents 
3.2.1 Synthesis of the post-PEGylation reagent N-hydroxysuccinimidyl-
hydrazone poly (ethylene) glycol pyridyldisulfide (NHS-HZN-PEG-
OPSS) 10 kDa 
This bifunctional and pH-sensitive reagent enabled further modifications at the ω- 
end of the PEG chain. Beside an activated ester for amine binding at one end of the 
PEG chain (α) the new reagent contained a pyridyldisulfide as the second reactive 
group at the other end (ω).  
First the disulfide content of the commercially available OPSS-PEG-NHS was 
determined by DTT cleavage assay. The percentage of arisen pyridine-2-thione was 
found to be 77 +/- 7% indicating that the content of disulfide bonds in the original 
PEG reagent was significant different from 100%. The conjugate was generated in 
anhydrous DMF by first reacting the amino group of 1-amino-3,3-diethoxypropane 
(ADEP) with the activated ester of bifunctional PEG-reagent OPSS-PEG-NHS to form 
a stable amide bond. The following figure 17 illustrates the individual reaction steps 
towards the pH-labile OPSS-PEG-HZN-NHS reagent. 
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Figure 17) Synthesis of bifunctional post-PEGylation reagent by implementation of ADEP with 
OPSS-PEG in a 5 to 1 molar ratio. Reaction performed in water free DMF, excess ADEP was 
removed by size exclusion chromatography (Sephadex G25). After deprotection with HCl, the 
aldehyde was reacted with SHNH as described before for the monofunctional PEG reagent.  
 
Excess of unreacted ADEP was removed by gelfiltration on a 10/30 Sephadex G25 
column. As ADEP was used in a 5 fold excess, 20 % of ADEP could couple at most. 
Analysis by TNBS assay showed a reaction efficiency of almost 100% as 
approximately 80% ADEP remained unreacted after the incubation period (see figure 
18). 
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Figure 18) Amount of ADEP detectable after gelfiltration on Sephadex G25. 1) 5 µmol of ADEP 
and 2) 5 µmol ADEP incubated with 1 µmol of OPSS-PEG before application onto the column. 
 
The protecting acetal group of the emerged reagent was transformed into the 
corresponding aldehyde by incubation in 0.1 M HCl for 1 h at RT. The product was 
subsequently freeze dried and resolved in DMF. Similar as for NHS-HZN-PEG, the 
introduced aldehyde was coupled to SHNH in a molar ratio of 1:4 to form OPSS-
PEG-HZN-NHS. The reaction efficiency between SHNH and the aldehyde was found 
to be practically 100% and was therefore comparable to the reaction of the 
monofunctional reagent. Excess of SHNH was completely removed by 
benzyloxybenzaldehyde beads with a 100 fold molar excess of bead -CHO groups 
over SHNH as it was already used before for the monofunctional reagent.  
3.2.2 Synthesis of Alexa488-disulfide poly(ethylene) glycol (hydrazone-) 
N-hydroxysuccinimidylester (Alexa-SS-PEG-(HZN)-NHS) 
For visualisation of the deshielding ability of the PEG coat a hydrazone containing 
PEG conjugate with a fluorescent dye molecule (Alexa488) on one end was 
generated. The bifunctional pH-sensitive PEG derivative, Alexa-SS-PEG-HZN-NHS 
and its stable control counterpart Alexa-SS-PEG-NHS (Figure 19) were prepared by 
mixing OPSS-PEG-(HZN)-NHS in water-free DMF with Alexa488-SH. 
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Figure 19) Synthesis of the corresponding Alexa-labelled post-PEGylation reagent. Reagents 
were mixed with Alexa488-SH in a molar ratio of 1:1 in waterfree DMF. Process of the reaction 
can be monitored by measuring the release of pyridine-2-thione at 343 nm. 
 
The accordant Alexa with a free thiol group (Alexa-SH) was synthesized by reaction 
of Alexa Fluor® 488 carboxylic acid, succinimidyl ester with cysteamine.  
Before mixing the components, cysteamine was analyzed for its –SH content via 
Ellman´s assay and was found to be ~ 95 of declared 98%. This value decreases 
rapidly when the substance is not handled with care and not stored under argon. 
Reaction efficiency between cysteamine and the active ester of Alexa was 
determined via TNBS assay on decrease of free amino groups (as described before) 
and was found to be approximately 90%. The efficiency of the coupling reaction 
between cysteamine modified Alexa-succinimidylester and OPSS-PEG-(HZN)-NHS 
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could be monitored by the release of pyridine-2-thione at 343 nm. For the stable PEG 
reagent 69% and for the labile one 67% coupling of Alexa-SH could be measured. 
Finally, all synthesized conjugates and the stable OPSS-PEG control were analyzed 
for their ester reactivity and thus their ability to PEGylate amino groups. For all tested 
reagents ester reactivity was found to be at least 80%. 
 
 
 
 
 
 
 
 
 
 
Figure 20) Ester reactivity of the final PEG reagents was tested by incubation with 
ethanolamine for 1 h at room temperature and subsequent analysis of remaining –NH2 groups 
by TNBS assay. 
 
3.2.3  Shielding of polyplexes with bifunctional PEG reagents 
Figure 21 shows the titration curves for determination of the amount of post-
PEGylation reagent necessary to achieve polyplexes with a near neutral surface 
charge shielded with the bifunctional PEG reagents. Therefore, polyplexes were 
mixed with increasing amounts of the activated ester PEG reagents OPSS-PEG-
HZN-NHS and OPSS-PEG-NHS of 10 kDa. The PEG content of the targeting 
conjugate led to a partial shielding effect. Thus, the starting zeta potential of BPEI-
PEG-EGF containing particles was lower than that of untargeted polyplexes. For 
BPEI particles a molar excess of PEG molecules over BPEI molecules of 
approximately 30 fold generated shielded particles with a zeta potential below 5 mV. 
Whereas shielding of LPEI particles, performed in low salt containing buffer (HBG), 
was different to shielding of BPEI polyplexes, as even with a much higher molar ratio 
of up to 180 fold excess of PEG the zeta potential could not be reduced to values 
near neutral. Due to these findings 10 kDa PEG reagents were used on BPEI 
polyplexes in later experiments. It appeared to be only a small difference in the molar 
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excess required for shielding by either the stable or reversible PEG reagent. This 
demonstrates that the activated ester of the synthesized hydrazone mediated PEG 
reagent has a similar activity towards amines as the commercially available stable 
NHS-PEG.  
 
 
 
Figure 21 A and B) BPEI polyplexes, N/P = 6 prepared in HBS 0.5x and C) and D) LPEI 
polyplexes, N/P = 6 prepared in HBG post-PEGylated with increasing amounts of indicated 
PEG-reagents (10 kDa) and corresponding zeta potential. Black triangles: -10% EGF and white 
squares: +10% EGF   
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
0 20 40 60 80 100 120 140
Molar excess of OPSS-PEG-HZN
Ze
ta
po
te
nt
ia
l [
m
V]
0
5
10
15
20
25
30
35
40
0 20 40 60 80 100
Molar excess of OPSS-PEG-HZN
Ze
ta
po
te
nt
ia
l [
m
V]
0
5
10
15
20
25
30
35
0 20 40 60 80 100
Molar excess of OPSS-PEG 
Ze
ta
po
te
nt
ia
l [
m
V]
0
5
10
15
20
25
30
35
0 20 40 60 80 100 120 140 160 180
Molar excess of OPSS-PEG 
Ze
ta
po
te
nt
ia
l [
m
V]
A)
C) D)
B)
BPEI
LPEI
RESULTS  62 
3.2.4 Fluorescence correlation spectroscopy (FCS) of Alexa-PEGylated 
polyplexes 
For direct visualisation of PEG deshielding the fluorescent dye Alexa488 was coupled 
to the distal end of a NHS-containing, heterobifunctional PEG molecule. Cleavage of 
the molecule from the polyplex was monitored by fluorescence correlation 
spectroscopy (FCS).  By comparing the diffusion velocities of Alexa, Alexa-PEG and 
Alexa-PEGylated polyplexes it was possible to determine whether the PEG-shield is 
still bound to the polyplex or not.  
 
Figure 22) Illustration of the measure principle of conducted FCS experiments. With increasing 
size of the molecule the dye is connected to the diffusion velocity decreases. 
 
 
To minimize background noise caused by free Alexa, PEGylated polyplexes were 
purified prior to FCS measurements. Additionally, stable and labile Alexa-PEG 
reagents had to be purified from free Alexa molecules as they were used for control 
measurements. 
3.2.4.1 Purification of Alexa-SS-PEG-(HZN)-NHS for FCS measurement 
Alexa-Succinimidylester and Alexa-SS-PEG conjugates, stable and labile, were 
measured as controls in the FCS experiment. Plain cysteamine modified dye was 
diluted to a 10 nM solution and PEG conjugates were purified from excess unbound 
dye molecules by size exclusion chromatography on a Sephadex G25 material on a 
10/30 column (Figure 23). 
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Figure 23) Elution profile of A) Alexa-SS-PEG-NHS and B) Alexa-SS-PEG-HZN-NHS from 
Sephadex G25 superfine column 10/30 with 20 mM HEPES/ 0.5 M NaCl and a flow rate of 
1ml/min. Fractions were analysed by absorbance at 488 nm and by PEG assay at 590 nm. Black 
line: PEG, dotted line: Alexa 
 
Spectrometrical analysis of collected fractions revealed that the first peak contained 
Alexa labelled PEG conjugates and the second peak unreacted dye. Determination 
of the distribution of Alexa in those two peaks allowed for calculating the percentage 
of Alexa coupled to PEG. The results showed slight batch to batch variations with an 
average of 55-65% of Alexa bound to PEG and 35-45% free.  
3.2.4.2 Different approaches for purification of stable or labile Alexa-PEGylated 
polyplexes for FCS measurement 
First PEGylation approaches with purified BPEI polyplexes and Alexa-SS-PEG or 
Alexa-SS-PEG-HZN contained about 70% free Alexa-PEG conjugates and unbound 
Alexa dye and did not allow for valid FCS measurements. To achieve maximum pure 
polyplexes for FCS measurements different methods were investigated for their 
success in removing excess unbound Alexa–PEG conjugates, unlabelled PEG-
reagents and free dye molecules. 
3.2.4.2.1 Purification of stable and labile Alexa-PEGylated BPEI particles for FCS measurement 
via SEC 
As BPEI polyplexes were prepared at an N/P ratio of 6 in HBG, > 50% of BPEI is free 
in solution (66). To achieve as much as possible defined Alexa-labelled particles, the 
underlying BPEI polyplexes had to be purified from excess free BPEI in order to 
avoid PEGylation of free PEI polymer. This was achieved by SEC with a self made 
Pasteur pipette (see 2.14 (67)). The first peak (fraction 3 to 7) contained ~ 40% and 
the second (fractions 16 to 25) ~ 60% of BPEI and was determined via TNBS assay. 
DNA was detected spectrometrically at 260 nm and was found exclusively in the first 
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peak (see figure 24). Total recovery of BPEI was 86% and 88% for DNA. N/P ratio 
was reduced from 6 of unpurified to 2.35 of purified polyplexes which is in 
accordance with data from literature (66).  
 
 
 
 
 
 
 
 
 
Figure 24) Elution profile of BPEI polyplexes prepared in HBG at an N/P ratio of 6 eluted from 
Sephacryl S200 column material in a Pasteur pipette (custom made). BPEI was detected by 
TNBS assay     and DNA content by UV measurement at 260 nm    . 
 
Afterwards purified polyplexes were post-PEGylated with either Alexa-SS-PEG-HZN-
NHS or Alexa-SS-PEG-NHS. A second purification step was employed to remove 
unreacted Alexa-SH and Alexa-PEG conjugates (Figure 25). Similar elution profiles 
monitoring UV/VIS (260/488 nm) detection and PEG content of the individual 
fractions were obtained for stable and labile PEGylated polyplexes. PEG assay 
showed two peak values but no base line separation. Detection of Alexa gave 3 
peaks, with the first two of them showing no baseline separation. Besides PEG and 
Alexa, peak 1 contained DNA, indicating elution of Alexa-PEGylated polyplexes 
whereas peak 2 contained only unbound Alexa-PEG conjugate. DLS measurements 
showed particles with a hydrodynamic diameter of around 150 nm in the pool 
belonging to peak 1 but no particles could be detected in the fractions of the second 
peak. Finally, at fraction 50 free Alexa-dye molecules were eluted. 
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Figure 25) Purified BPEI polyplexes were Alexa-PEGylated and applied onto Sephacryl 200 
column 10/30 in HBG/0.5 M NaCl. Absorbance of Alexa dye at 488 nm    and absorbance of PEG 
at 590 nm, determined by PEG assay     . 
 
3.2.4.2.2 Purification of Alexa-PEGylated polyplexes: Dialysis 
One attempt to generate pure Alexa-PEGylated BEI polyplexes was the performance 
of a dialysis. There was no difference detectable whether the membrane with 14000 
or 25000 Da MWCO was used. For both membranes the amount of removed PEG 
varied between 5 and 15%. In parallel, spectrometric analysis of Alexa at 488 nm 
showed that only ~10% of totally applied Alexa dye molecules were removed. Hence, 
measurement of dialysed particles in FCS was not possible as too much of free dye 
was still present. 
3.2.4.2.3 Purification of Alexa-PEGylated polyplexes: Electrophoresis 
Another purification attempt was performed with the so called Electro Prep® system. 
Although Alexa as well as unbound and hydrolysed PEG-conjugates exhibit negative 
charge moieties, analysis of samples taken before and after electrophoresis showed 
that neither PEG nor Alexa content was reduced after 20, 30 or 60 minutes.  
3.2.4.2.4 Purification of Alexa-PEGylated polyplexes: Vivaspin® 
For ultraconcentration, PEGylated complexes were applied on Vivaspin® 6 
microconcentrators. Approximately 100% of PEGylated complexes (generated in 
HBG) could be recovered in the supernatant as UV measurements at 260 nm 
revealed. Independent of the used molecular weight cut-off, ~80-90% of PEG was 
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found in the filtrate. Similar results were measured for Alexa (see table 3). The 
ultracentrifugation devices of different molecular weight cut-offs showed an efficient 
removal of undesired molecules. PEG as well as Alexa was removed (= found in the 
filtrate) in similar amounts from the polyplexes which remained mainly in the 
supernatant. Further centrifugation steps could not increase the separation of 
conjugates from the polyplexes anymore (data not shown). Such purified particles 
were then applied for FCS measurements; however, they did not allow for valid 
interpretation as the amount of free dye in the samples obviously exceeded a 
tolerable amount. 
 
 
 
 
 
 
 
 
Table 3) Summarisation of polyplex purification using Vivaspin® ultracentrifugation. Stable 
Alexa-PEGylated BPEI polyplexes N/P = 6 in HBG were centrifuged in microconcentrator tubes 
of indicated MWCO at 4000 g for 5 min. Supernatant and filtrate were analysed 
spectrometrically for DNA and Alexa content and the amount of PEG was determined by PEG 
assay. 
 
3.2.4.2.5 Purification of Alexa-PEGylated polyplexes: Dextran-cushions 
In a preliminary experiment, BPEI polyplexes were centrifuged at 16000 g, afterwards 
the obtained pellet was resuspended in HBG in an ultrasonic bath and was filtrated 
through a paper filter. Size measurement of these particles revealed aggregates with 
high polydispersity. When in contrast, such polyplexes were centrifuged onto dextran 
cushions using only 4000 g, no proper pellet occurred. After solving the upper 
dextran layer in HBS 0.5x, particles with approximately 300 nm could be detected via 
DLS. When Alexa-PEGylated particles were centrifuged onto this dextran cushion the 
recovery was approximately 70%. Size and zeta potential measurements of the 
resuspended PEGylated polyplexes showed particles of 160 nm with a zeta potential 
of approximately 4 mV. However, measurement of such purified Alexa-PEGylated 
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polyplexes in the FCS set-up was not possible as still too much free dye molecules 
were present. 
3.2.4.2.6 Purification of Alexa-PEGylated polyplexes: Anion exchange chromatography 
Application of Alexa-PEGylated polyplexes on a DEAE anion exchange 
chromatography column and elution with 0.5 M salt containing 20 mM HEPES buffer 
revealed an elution profile with no separation since almost all PEG containing 
components were eluted immediately, free 488 was eluted at last. 
Subsequent analysis in FCS showed high standard deviations between the single 
measurement results representing values of free dye molecules as well as PEG-
bound Alexa-dye molecules.  
3.2.4.3 FCS results 
All Alexa-PEGylated polyplexes purified by the methods described above were 
analysed in the FCS experiment but interestingly only those achieved from the SEC 
experiment were pure enough to give clear signals.  
Alexa-PEGylated particles eluted in the first peak were initially analysed by DLS. Zeta 
potential was found to be +2 mV and the size approximately 150 nm. The time 
needed for passing the detection window correlates with the size of the molecule the 
dye is connected to. Plain cysteamine modified Alexa-succinimidylester molecules 
showed the shortest diffusion time of ~30 µs. Coupling of Alexa to either stable or 
labile bifunctional PEG reagent revealed diffusion times of around 200 µs. The 
longest diffusion times from 2000 to 6000 µs were found for Alexa-PEGylated 
particles with no significant difference detectable between stable and labile Alexa-
PEGylated polyplexes. After incubating the polyplexes for 4 h at pH 5.0 stable 
shielded polyplexes exhibited an unchanged diffusion time. In clear contrast, the 
sample with the pH-labile Alexa-PEGylated polyplexes exhibited a much faster 
movement of ~ 200 µs, similar to the diffusion time of Alexa-PEG conjugates. These 
data indicate clearly the pH induced cleavage of the dye labelled PEG molecules 
from the polyplex. Results are summarised in table 4. 
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Table 4) Summary of the results of the FCS analysis of Alexa-PEGylated complexes. For each 
sample 10 measurements with sampling time of 30s were performed. The 488 nm line of an 
argon laser was utilized for fluorescent excitation. Emission light was split by a dichroic mirror 
and was collected by an Avalanche Photodiode (APD) with a 505-530 nm filter and a pinhole of 
78 µm.  
 
3.2.5 Determination of polyplex composition 
In this additional experiment it was shown how much Alexa-SS-PEG conjugate can 
bind to BPEI integrated in a polyplex and, in comparison, how much can bind to free 
BPEI polymer. In a preliminary experiment BPEI was reacted with a 30 fold molar 
excess of Alexa-SS-PEG-NHS and after 1 h reaction time a cation-exchange 
chromatography was performed. In figure 26 A) the corresponding elution profile is 
shown. PEG and Alexa are eluted simultaneously with one higher peak at the very 
beginning in low salt containing buffer (0,5 M) and a second peak that is much 
smaller which is eluted only at high salt concentrations (3 M). Analysis via TNBS 
assay revealed that BPEI is eluted only in fractions with 3 M salt. Taken together one 
can see that first the bigger part of Alexa-PEG was eluted followed by a small fraction 
that has obviously coupled to BPEI as it is retained and is not eluted until a high 
amount of salt is present on the column. 
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Figure 26) Elution profiles of Alexa-PEG (30 fold molar excess) coupled to A) BPEI and B) 
purified BPEI polyplexes N/P = 6. Grey triangles PEG via PEG assay, black squares Alexa, 
white squares BPEI via TNBS assay and black line in B) absorbance at 260 nm (AU = 
absorbance unit) 
 
Polyplexes purified by the method described under 2.14.1 used for FCS experiments 
were analysed for their detailed composition. In Figure 26 B), the same experiment 
as described above but based on BPEI polyplexes is shown. In order to determine 
the amount of Alexa-PEG bound to BPEI chains on the particle’s surface the whole 
complex was dissociated by addition of high NaCl concentration and was applied 
onto the cation exchange column.  
Before disintegration these purified BPEI polyplexes had a size of ~ 100 nm before 
and ~ 150 nm after Alexa-PEGylation. Measurement after adjusting the polyplex 
solution to 1.5 M NaCl revealed that no discrete particles were present anymore. The 
polydispersity index, measure of size distribution, was found to be 1 indicating that no 
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homogenous particle population was present anymore with data reaching from a few 
to a thousand nm.  
Apart from the additional line, UV absorbance at 260 nm, the profile is similar to that 
of plain polymer. Fractions being positive in TNBS assay were pooled and further 
analysed for their absorbance at 488 nm. Before calculating the amount of PEG the 
ratio Alexa to PEG of the utilized Alexa-SS-PEG-NHS batch was determined as 
described under 2.13 and was found to be 1 µmol PEG to 0.45 µmoles of Alexa 
resembling a ratio of 2.2 to 1. This ratio was then used to determine the amount of 
PEG corresponding to the measured Alexa absorbance in the BPEI fraction. The 
calculated ratios are shown in the following table 5. When Alexa-SS-PEG-NHS was 
reacted with free BPEI polymer the ratio PEG to PEI was found to be approximately 3 
compared to 1.3 when coupling was performed to purified BPEI polyplexes. 
Calculating the ratio by PEG assay instead via the Alexa absorbance lead to very 
high values. These increased values are typically when PEI and PEG coexist in the 
analysed solution and demonstrate that PEI interferes with the PEG assay. Therefore 
no useful values were obtained in the second assay. Nevertheless, for both ways of 
calculation, values for PEGylation of free polymer are higher than those achieved for 
PEGylation of PEI within purified polyplexes. 
 
Table 5) Ratio of PEG to BPEI either coupled to free polymer or to DNA bound polymer 
calculated by absorbance of Alexa488 in comparison to values achieved by PEG assay 
analysis. The latter values are not considered as real due to an interference of PEI with the PEG 
assay under the given conditions (diluted solutions, high salt). 
0.9 +/- 0,16 : 12 +/- 0,17 : 1PEG: LPEI
(Abs. 488)
1,3 +/- 0,2 : 13,3 +/- 1 : 1PEG: BPEI 
(Abs. 488)
PEI polyplexPEI polymerAlexa-PEG-NHS
coupled to:
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4 DISCUSSION 
Designing chemically dynamic structures for non-viral delivery of nucleic acids into 
cells is a novel approach to mimic the intracellular dynamics of viruses which have 
naturally evolved for optimal delivery of their genetic payload. Several strategies like 
enzymatic activation or redox- and pH- responsive approaches have already been 
applied (for recent review see (74)). 
PEI and PEI derived polymers are examined intensely in the area of non-viral gene 
delivery. One major advantage of synthetic gene vectors is that in comparison to viral 
vectors they can quite easily be chemically modified and therefore allow for adaption 
to a variety of local conditions they are exposed to on their way to the target cell, 
upon arrival at the target cell and finally inside the target cell. A negative side effect of 
PEI based gene delivery systems is that they exhibit a dose dependent articulate 
cytotoxicity. This cytotoxicity occurs mainly due to the interaction of the positively 
charged polymer with negatively charged moieties like membranes and proteins or 
other blood components. Introduction of the hydrophilic polymer PEG to PEI reduced 
its cytotoxicity, increased the circulation time of PEI based polyplexes and their 
solubility. These positive effects were accompanied by the fact that the transfection 
efficiency, already much lower than that of viral vectors, was reduced severely. Even 
though the incorporation of targeting ligands increased the transfection efficiency it 
was not restored to that of non-PEGylated polyplexes.  
Important steps during transfection are particle association with the cell membrane, 
uptake by endocytosis followed by endosomal release, nuclear trafficking, import of 
the gene into the nucleus and finally its transcription. Each of these steps can 
potentially be influenced by PEGylation of the vector. Polyplexes that are taken up by 
receptor mediated endocytosis are at first localized in endosomal vesicles. Escape 
from such vesicles is a well-known bottleneck for successful gene delivery. 
Therefore, the idea came up that it might be advantageous if the PEG shield could be 
removed in the endosome, re-exposing the positive surface charge of the polyplex 
and thus allowing for increased membrane interactions and therefore increased 
endosomal escape. 
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Recently Walker et al. demonstrated that hydrazone based pH-sensitive shielding of 
PEI polyplexes successfully improved the transfection ability of such PEGylated 
polyplexes in vitro and in vivo. This approach used the so called pre-PEGylation 
method (as described in 1.2.3.1) for generation of shielded polyplexes. pH-sensitive 
PEGylation utilizes the advantages of PEGylation, like extended circulation time, 
reduced cytotoxicity and less unspecific interactions (25) and simultaneously 
overcomes its appertaining disadvantage of reduced endosomal release (27; 28) 
through the specific reversibility of the PEG-shield. A couple of research groups have 
already successfully applied pH-sensitive PEGylation but so far always in a pre-
PEGylation approach where PEG is coupled in a pH-labile manner to a polycation or 
a lipid before DNA is added (59; 60; 75). The question was, whether it would be 
possible to synthesize a similar PEG reagent but in form of a post-PEGylation 
reagent (described under 1.2.3.2). One of the main advantages of a pH-labile post-
PEGylation reagent is that it can be applied more flexible to almost any system 
bearing amine groups. An interesting target could be the application onto viral 
systems as PEGylation of viral capsid proteins is feasible and has already been 
shown to improve the practicability of viral particles (21) in terms of in vivo 
applications. Furthermore the addition of the hydrophilic polymer PEG after DNA 
condensation cannot interfere with particle formation. Finally, post-PEGylation in 
combination with the described purification method turned out to allow for generation 
of better characterized and well defined polyplexes. Removal of free PEI and other 
unbound molecules also results in reduced cytotoxicity (67)  
4.1 Synthesis of monofunctional NHS-HZN-PEG 
Numerous pH-sensitive reagents for drug delivery have been developed after it 
became evident that these reagents, once internalized into endosomes, encounter an 
increasingly acidic environment that can be used for triggering cargo release. Many 
research groups have contributed to the "triggered" approach to drug delivery by 
preparation and characterization of acid-sensitive modified drugs (76), cationic lipids 
(77), liposomes (64) or polyplexes (28). Whereas the last three references 
mentioned, applied hydrazone based chemistry. Other approaches utilized ortho 
esters (75; 78) or acetals (59; 79) for pH triggered release. The aim of this study was 
to build on previous experiences with acid labile PEG shielding of polyplexes by 
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preparing a novel hydrazone-based PEG reagent suitable for post-PEGylation of 
gene delivery systems. The post-PEGylation strategy was chosen due to the reasons 
mentioned above with the ulterior motive to generate a pH-sensitive PEGylation 
reagent that could also be tested for its applicability on viral vectors. This has been 
examined in cooperation with the group of Prof. Kochanek at the University of Ulm 
(unpublished data).   
Direct coupling of PEG to PEI via hydrazone bonding to form a control pre-
PEGylation reagent was not possible due to autocatalytic activity of PEI which led to 
spontaneous cleavage of the PEG-HZN-PEI conjugate already after thawing. These 
findings are consistent with data published by Walker et al. (28) who showed that it is 
not possible to form a pre-PEGylation reagent by coupling PEI to a hydrazone 
bearing PEG whereas this linkage was feasible when PLL was used as the 
corresponding cationic polymer. Post-PEGylation approaches have already been 
conducted for several years (23; 33). Here it was analyzed, whether a PEG reagent 
that is coupled via a pH-sensitive linker improves gene transfer efficiency in 
comparison to a comparable stable coupled PEG reagent. Recently Knorr et al. (59) 
were able to generate such acid labile conjugates, but by bridging PEG to PEI via an 
acetal residue and using it as a pre-PEGylation reagent.  
To generate PEG with a terminal hydrazone group hydrolysable at low pH, SHNH 
was coupled to aldehyde functionalized PEG. The neighbouring pyridyl group in this 
reagent was intended to ensure stability at neutral pH and hydrolysis at pH 5, as such 
a behaviour was observed with a 2-pyridylhydrazone derivate in the PEG-HZN-
polylysine conjugate mentioned above (28). Reaction between PEG-aldehyde and 
the hydrazine group of excessively applied SHNH occurred almost completely. 
Difficulties were merely caused by unreacted SHNH as its activity towards amine 
groups competes with that of the ultimate reagent. Removal of excess SHNH had to 
occur under water-free conditions and was finally achieved by immobilisation onto     
–CHO groups bearing polystyrene beads. 
4.1.1 Shielding and deshielding of polyplexes 
NHS-HZN-PEG synthesized for acid triggered deshielding of gene vectors was first 
tested on its shielding ability and thereby compared to a stable control reagent. PEI 
polyplexes above a molar ratio of PEI nitrogen to DNA phosphate of 3 bear a net 
positive surface charge (23; 80). Nevertheless, to achieve sufficient transgene 
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expression, polyplexes with N/P ratios of 6 or higher are commonly used (66; 67). In 
this case, the zeta potential of polyplexes is usually in the range of +30 mV, which 
triggers activation of complement and plasma protein binding after systemic 
application (23). Initial studies with post-PEGylation of BPEI based polyplexes 
revealed that a 10/1 PEG/PEI (w/w) ratio of PEG 5 kDa enabled significant shielding. 
This is in good correlation with the data obtained in figure 11A, where a molar ratio of 
PEG (20 kDa) to BPEI (25 kDa) of 20/1 (corresponding to a PEG/PEI (w/w) ratio of 
16/1) reduced the surface charge of BPEI polyplexes by almost 50%. For LPEI 
polyplexes a significantly higher molar excess was necessary to achieve surface 
shielding. This can be explained by the fact that in contrast to BPEI, where on 
average every third nitrogen is a primary amine, LPEI only contains one primary 
amine per molecule with the remaining being secondary ones. It was observed that 
the reactivity of the PEG-succinimidyl ester in aqueous solution is much lower 
towards LPEI (32), which is due to the differences in the pKa value between primary 
and secondary amines. The incorporation of the EGF-PEG-BPEI conjugate into the 
polyplex already reduced the initial surface charge of the polyplex, which is most 
probably due to the presence of PEG-EGF, as similarly observed with transferrin 
containing PEI polyplexes (23; 81). There was no significant difference whether 
stable or labile PEG reagent was applied in the shielding experiment. This was 
expected as both of them offered similar ester activity in a preliminary experiment.  
By measuring size and corresponding zeta potential of such pH-labile PEGylated 
polyplexes among conditions resembling those found whilst blood circulation (pH 7.4) 
and inside the endosome (~ pH 5.0) it was shown how shield removal at acidic pH 
changes the biophysical properties of the particles. The dynamic of acid triggered 
deshielding of HZN-PEG modified polyplexes was monitored by zeta potential 
measurements over time at pH 5.0. Complete deshielding was obtained after 2 h, 
whereas the HZN-PEG shield remained stable at pH 7.4 for at least 4 h. Additionally, 
it was observed that LPEI based polyplexes aggregated after PEG cleavage, which 
can also be beneficial for its endosomolytic properties (see below). This confirms the 
usefulness of the PEG linking strategy chosen to stabilise polyplexes at neutral pH 
and enable their deshielding at acidic pH. Stability of the PEG shield for at least 
several hours seems sufficient, as the half life of post-PEGylated polyplexes in the 
bloodstream of mice after intravenous injection is approximately 30 minutes (23; 81-
83). Additionally it has been shown by de Bruin et al. (84) that uptake of PEGylated 
DISCUSSION  75 
and targeted polyplexes in vitro occurs within minutes therefore the stability of pH 
labile PEGylated particles over 4 h offers by far enough time to be enriched in a 
certain tissue and to be taken up in form of small and discrete particles.  
4.1.2 In vitro transfection efficiency 
Transfection efficiency was mainly influenced by the used polymer, whether the 
polyplex was PEGylated or not, whether EGF targeting ligand was incorporated or 
not and finally whether stable or labile PEGylation was chosen. 
As already shown in many other examinations the LPEI based polyplexes led to 
higher transfection values as BPEI polyplexes did  (85; 86). LPEI is known for a 
strong tendency to aggregate on and also inside the target cells (7), which leads to 
enhanced endosomolytic activity due to higher amount of PEI present in the 
endosome (87). Further on LPEI polyplexes form looser condensates with plasmid 
DNA compared to BPEI polyplexes (88) and are therefore supposed to allow for 
facilitated DNA release during the transfection process.  
For both BPEI and LPEI polyplexes, PEGylation strongly reduced luciferase gene 
expression. This is at least partially due to reduced cellular binding and uptake. 
Similar observations were made on EGF-receptor expressing HuH7 cells using the 
pre-PEGylation strategy (84). 
In the case of EGF-containing polyplexes PEGylation does not significantly hamper 
cellular binding and internalisation (84; 89). Incorporation of EGF as targeting ligand 
led to increased gene transfer into HuH7 and Renca-EGFR cells but transfection 
ability was not restored to the values achieved by non-PEGylated polyplexes which is 
in accordance with literature (90; 91). Apparently intracellular events like hampered 
endosomal release are supposed to be responsible for this effect (28). PEGylation 
can negatively affect the transfection process by several mechanisms. In the case of 
targeted polyplexes PEG can negatively interfere by hiding the cell targeting ligand 
or, in the case of a post-PEGylation strategy, can covalently modify the ligand when 
using amine reactive PEGylation reagents and a ligand containing primary amines in 
the side chain, e.g. transferrin (89). Post-PEGylation of polyplexes containing murine 
EGF has the advantage of not interfering with EGF binding activity, as murine EGF 
does not contain lysine residues. To prevent obstruction of EGF within the PEG layer 
EGF was coupled via a PEG spacer of sufficient length (see also Blessing 2001 
(33)).  
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In these experiments a clear benefit of the labile PEG shield can be observed 
compared to stable PEG shielded polyplexes. Even with untargeted LPEI polyplexes 
labile PEG shielding led to higher transgene expression indicating that PEGylated 
polyplexes internalised by adsorptive endocytosis can benefit from this principle.  
4.1.3 In vivo transfection efficiency 
Finally, the potential of labile PEG shield to enhance efficiency and selectivity of 
transgene delivery to tumour tissue after systemic application was evaluated. From 
literature it is known that besides the size, biodistribution of polyplexes after 
intravenous administration is modulated by the surface charge of the particle (23). If 
their surface is hydrophilic and uncharged they are less taken up by phagocytic cells 
of the RES, aggregation can be avoided and the circulation time is significantly 
prolonged. Unfortunately, coating of the positive surface charge with PEG leads to 
comparably low cell transfection efficiency at the same time (26; 31; 92). For 
improved targeting of DNA complexes to EGFR overexpressing cancer cells, 
polyplexes have to be small enough to pass through the fenestrations in the tumour 
vasculature and should be provided with a suitable targeting ligand, like EGF in the 
present case. This was achieved by post-PEGylation of BPEI or LPEI particles 
containing 10% of BPEI-PEG-EGF. PEGylation protects the polyplexes from 
aggregation and therefore they maintain their size. The data clearly show that both 
the labile and stable PEG shield provide sufficient protection within the bloodstream, 
as the lung expression levels observed are very low. This indicated that no gross 
deshielding and aggregation took place in the blood, as usually lung expression with 
unshielded and aggregating BPEI and LPEI polyplexes is several orders of 
magnitude higher (see e.g. (7)). In the tumour tissue the labile PEG shield led indeed 
to a beneficial effect, most probably on the cellular level, as EGF-LPEI polyplexes 
with labile PEG shield were significantly more efficient than the corresponding 
formulation with a stable shield. With BPEI polyplexes the advantage of the pH-labile 
PEG-shield was also detectable but as already shown in the in vitro experiment the 
values were lower and less significant as with LPEI as basic polymer. 
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4.2 Synthesis of bifunctional NHS-HZN-PEG-OPSS 
A bifunctional PEG reagent offers the opportunity to further modify the PEGylated 
polyplex for example by introducing a targeting ligand to the PEG reagent. Post- 
targeting after PEGylation of polyplexes has already been successfully performed by 
Blessing et al. (33) or Rao et al. (93). One advantage using a pH-labile post-
PEGylation reagent containing a targeting moiety is that the complete PEG shield 
could be removed inside the endosome. In the approach with monofunctional PEG 
the incorporated PEI-PEG-EGF conjugate cannot be cleaved among acidic 
conditions and thus hypothesized membrane interactions are constricted. 
Endosomally cleaved targeting ligand also cannot interfere with intracellular 
trafficking. 
 
 
 
 
 
 
 
Figure 27) Hypothesized occurrences of pH-labile PEGylated polyplexes in acidified 
endosomes. A) Polyplex containing BPEI-PEG-EGF introduced by pre-PEGylation and cleaved 
PEG chains. B) Polyplex with cleaved PEG-EGF and PEG chains allowing for increased 
membrane interaction 
 
Further on, post-targeting of PEGylated polyplexes could assure that the targeting 
ligand is best accessible to react with its suitable counterpart and is not hidden inside 
the PEG layer. Another problem with PEGylation of targeted polyplexes, PEGylation 
of the targeting ligand itself, can be easily avoided when the targeting ligand is not 
added until the polyplex is readily PEGylated. Future analysis of polyplexes that have 
been PEGylated with this bifunctional pH-labile PEG reagent followed by addition of 
–SH modified targeting ligands will show whether this approach brings additional 
advantages through removal of the whole PEG envelope inside the endosome 
compared to only partial removal. 
After the basic bifunctional acid labile PEG reagent was synthesized and tested for its 
shielding ability on LPEI and BPEI polyplexes its pH sensitivity was examined closer. 
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It was intended to visualise the pH induced cleavage of the PEG chains from the 
polyplex by FCS measurements with fluorescent dye labelled pH-sensitive PEG 
conjugates. For this purpose, the commercially available heterobifunctional OPSS-
PEG-NHS derivate was modified to harbour a hydrazone bonded succinimidylester 
and thus ensuring amine reactivity. Alexa488 fluorophore was modified with a thiol 
group by implementation with cysteamine. To prevent subsequent purification steps, 
where the presence of water would hydrolyse the succicimidyl ester, Alexa-
succinimidyl ester and cysteamine were added in stochiometric deficiency. This –SH 
modified Alexa allowed for carrying out defined coupling to OPSS-PEG-(HZN)-NHS 
by following the reaction by the release of the UV absorbing pyridine-2-thione at 343 
nm. As purification of Alexa-PEGylated polyplexes was required anyway, OPSS-
PEG-(HZN)-NHS was used in an excess over Alexa-SH for increased reaction 
efficiency. Even without following purification unlabelled PEG does not disturb the 
sensitive FCS set-up like free Alexa dye molecules would.  
4.2.1 Purification of BPEI polyplexes 
In this work two purification steps were conducted after particle formation. The first 
step removed unbound PEI from the polyplex and the second one was performed to 
remove unbound PEG and Alexa molecules.  
PEI is known for its cellular toxicity and severe systemic side effects. A standard PEI 
polyplex generated at an N/P ratio above 5 can contain up to 80% of free PEI which 
is not complexed with DNA (65; 94). Increasing N/P ratios are directly correlated to 
increased cellular toxicity (95); (96). A purification method via size exclusion 
chromatography has been established by Boeckle et al. (66) and indicated lower 
toxicity of purified polyplexes but simultaneously led to lower reporter gene 
expression. The main reason for purification lies in improvement of systemic 
applications of gene vectors with increased biocompatibility. Regarding the use of 
non-viral vectors in future gene therapy trials, it is of major importance to use purified 
and chemically well defined vector systems. 
In the present work Alexa-PEGylated polyplexes had to be analysed for shield 
removal in a FCS experiment. Any accessorily present PEI of an unpurified polyplex 
solution would become Alexa-PEGylated additionally and thus the background noise 
of the measurement would be too high. Purification of BPEI polyplexes can be 
achieved for smaller amounts by custom made Sephacryl S 200 HR filled Pasteur 
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pipettes or for larger amounts in 10/30 standard HPLC columns offering additionally a 
good possibility to determine the amount of DNA and PEI the polyplex is composed 
of before Alexa-PEG conjugates are added. 
4.2.2 Purification of Alexa-PEGylated polyplexes 
Post-PEGylation was carried out with a 30 fold molar excess of Alexa-SS-PEG-
(HZN)-NHS over BPEI. After Alexa-PEGylation of polyplexes different unreacted 
molecules are present in the reaction approach. Besides N-hydroxy-succinimide 
these are mainly negatively charged carboxylates, the hydrolysis-products of Alexa-
NHS, PEG-NHS and Alexa-SS-PEG-NHS.  
First FCS measurements of Alexa-PEGylated polyplexes revealed more than 70% of 
free Alexa and Alexa-PEG conjugates and thus did not allow for valid interpretation of 
the obtained data. Therefore a suitable purification method was searched for. 
Purification via size exclusion chromatography on Sephacryl 200 column material did 
not lead to baseline separation between the peak of Alexa-PEGylated polyplexes and 
the one containing free Alexa-PEG conjugates. Thus, it did not seem to be the 
purification method of choice. A number of different strategies to remove unbound 
conjugates was tested additionally.  
For technical reasons PEI polyplexes were always purified prior to Alexa-PEGylation 
in all the conducted experiments. BPEI was used for DNA condensation, as it is less 
responsive to the presence of salt than LPEI is and most of the purification 
approaches were performed in HEPES buffer with 0.5 M salt. 
As already mentioned size exclusion chromatography with Sephacryl 200 did not 
lead to baseline separation of Alexa-PEGylated particles and free PEG reagents but 
FCS analysis finally demonstrated that samples taken out of the first fractions of the 
polyplex containing peak were well applicable for this kind of analysis. 
If the other approaches, like Dialysis, Electrophoresis (with the ElectroPrep® 
System), density centrifugation (into dextran cushions), anion exchange 
chromatography and ultra centrifugation (with Vivaspin® columns) would be further 
optimized, probably another purification method would be available additionally. 
The importance of generating well defined and purified non-viral gene carriers has 
already been demonstrated by Boeckle et al. and Fahrmeir et al. (66; 67) and in vivo 
applications of such purified polyplexes clearly indicated their improved compatibility. 
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In this present work, purification was only performed to enable FCS measurements 
but self-evidently the described method could also be used to generate purified post-
PEGylated polyplexes for biological characterization. Purification methods identical to 
those applied in former investigations regarding pre-PEGylated polyplex formulations 
could not be used analogously as the focus of this work lies on post-PEGylation. 
Considering pre-PEGylation approaches, shielding compounds are always coupled to 
positively charged polycations and therefore require a different strategy for 
successful removal. Removal of excess polymer and other components leads to well 
defined polyplexes. This displays two big advantages. First, most of the toxic side 
effects are caused by free polymers and/or side products and thus purified 
polyplexes are much better tolerated. Second, thinking about GMP production it is 
absolutely mandatory that the employed substances are exactly defined. This can be 
achieved with purification methods and determination of compounds being included 
in or separated from the ultimate product.  
4.2.3 Fluorescence correlation spectroscopy 
Fluorescence correlation spectroscopy (FCS) allows to measure the diffusion velocity 
of fluorescently labelled molecules and is therefore a valuable tool for analysing 
dynamic processes related with assembly and disassembly of macromolecular 
structures like polyplexes (97; 98). Rusu et al. followed the binding of fluorescent 
labelled peptides to lipid vesicles via FCS measurements. The large unilamellar 
vesicles were significantly larger than the peptide and therefore the correlation times 
for the free and bound peptide could be distinguished using single colour 
autocorrelation measurements (99). Here, this method was utilized to unambiguously 
show the cleavage of PEG from the polyplex’ surface at acidic pH. FCS 
measurements of Alexa-PEG exhibited a very narrow distribution of individual 
measurements with a standard deviation of five percent, which indicated that i) no 
significant amounts of free Alexa dye are present in the Alexa-PEG conjugates and ii) 
the PEG 10 kDa has a narrow size distribution.  
Alexa-PEG modified BPEI polyplexes had a rather broad size distribution at neutral 
pH, which can be explained by certain heterogeneity in size commonly observed for 
such preparations. In contrast, incubation at acidic pH apparently led to complete 
cleavage of the Alexa-PEG shield, as the signal obtained was similar to that of free 
Alexa-PEG. FCS measurements of polyplexes shielded with the dye labelled 
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bifunctional pH-labile PEG conjugate represent a nice way to visualise the cleavage 
of the PEG chain amongst acidic conditions. 
4.2.4 Determination of polyplex composition 
As already mentioned before, it is of great importance to get insights into the detailed 
composition of a certain polyplex in order to assure reproducibility. For this 
experiment purified polyplexes were first Alexa-PEGylated and afterwards completely 
disintegrated by the addition of salt to a final concentration of 1.5 M NaCl. Adding 
such a high salt concentration leads to abolition of the electrostatic interaction 
between negatively charged DNA and positively charged polymer (100; 101). 
Therefore this demonstrates a good starting base for analysis of accurate polyplex 
composition. The data provide information on final percentages of BPEI polymer and 
DNA and therefore the N/P ratio of the purified core particles. Additionally, the 
PEGylation degree and the amount of Alexa-PEG conjugates in the final particles are 
clarified. The composition of such purified particles was analysed after disassembly 
in high salt containing HBG. Polyplexes that are applied to increasing amounts of 
NaCl become separated into polymer and DNA at a salt concentration of 
approximately 1.1 M as demonstrated in the following figure. 
 
 
 
 
 
 
 
Figure 28) A schematic presentation of complex behaviour when ionic strength is increased by 
addition of salt.  
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separate DNA, unbound PEG, Alexa and Alexa-PEG from PEI and from Alexa-
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retained by the negatively charged sulfonyl groups of the column material whereas 
DNA, unbound (Alexa)-PEG and Alexa molecules should be separated as they do 
not bind and are eluted first. The idea was to use the absorbance of Alexa488 in 
order to indirectly calculate the corresponding amount of PEG coupled to BPEI. The 
ratio Alexa to PEG can be determined in advance by separating unbound Alexa from 
(Alexa)-PEG conjugate via gelfiltration on Sephadex G25. As expected more PEG 
could bind per BPEI molecule when the reaction was performed with free BPEI 
polymer (3.3 PEG per PEI) compared to polymer bound to DNA (1.3 PEG per BPEI). 
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5 SUMMARY 
Gene transfer efficiency of current non-viral vectors is by far not as efficient as that of 
their viral analogues. Natural viruses are perfectly attuned to invade cells and to 
deliver their genetic load. Therefore they represent a convenient example to teach us 
how to further optimize polycationic gene carriers in order to overcome most of the 
typical hurdles like specific cell targeting, endosomal release, vector unpacking and 
nuclear import that restrict the success of non-viral vectors.  
The fact that viruses can exploit the decreasing pH of endosomal vesicles to change 
their appearance in a way that they can escape these “traps” was taken as a model 
for this thesis to design non-viral gene vectors that are likewise subjected to 
structural transformation upon acidification. Recent publications gave hints that 
PEGylation of PEI based polyplexes might hamper their endosomal escape 
properties and thus contribute to the decreased transfection ability of such PEGylated 
polyplexes.  
The aim of the thesis was to create a pH-responsive PEGylation reagent which can 
overcome this hurdle and which is not restricted to non-viral vectors like the pre-
PEGylation approach is.  
A 20 kDa post-PEGylation reagent was synthesized containing a hydrazone moiety 
for pH-sensitive cleavage and an activated ester for polyplex coupling. This reagent 
showed similar shielding ability on PEI based polyplexes as the commercially 
available stable PEG-NHS ester. Depending on the underlying polymer, branched or 
linear PEI, deshielding of the PEG shield under acidic conditions could be shown 
indirectly by zeta or size measurements. Due to deshielding, BPEI polyplexes 
showed an increasing zeta potential after incubation in salt containing buffer at pH 
5.0 whereas LPEI polyplexes started to aggregate under the same conditions making 
reliable zeta potential measurements impossible. For biological characterisation PEI 
based polyplexes with or without EGF as targeting ligand were PEGylated with the 
pH-labile PEG reagent and tested on HuH7 and Renca-EGFR cells, both 
overexpressing the EGF receptor. Branched and linear PEI based polyplexes 
showed significant improvement in gene transfer efficiency with the pH-labile PEG 
reagent compared to the stable analogue. These promising in vitro data gave rise to 
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an in vivo experiment where stable shielded branched or linear, EGFR targeted PEI 
polyplexes were compared to those shielded with the acid cleavable PEG reagent. A 
clear advantage of the pH-sensitive PEG shield could be observed.  
Additionally, a bifunctional pH-sensitive PEGylation reagent was synthesised which 
offers a starting base for retargeting experiments by ligand-coupling via disulfide 
bond formation to PEGylated gene carriers. This reagent was applied for coupling the 
fluorescent dye Alexa488. The Alexa488 containing pH-sensitive PEG reagent was 
used for shielding of BPEI polyplexes and for visualisation of the pH dependent 
cleavage process. Diffusion velocities of these particles were determined by FCS 
measurements and cleavage of the dye labelled PEG chains from the particle was 
found only for the labile Alexa conjugate indicated by a significant increase of velocity 
after incubation at pH 5.0. The need to purify the dye labelled polyplexes used for the 
delicate FCS measurement led to the development of a purification method that 
allowed for calculation of the final composition of the PEGylated polyplex and thus 
offering a possibility to verify the reproducibility of each sample batch. 
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6 APPENDIX 
6.1 Abbreviations 
 
Abs.   Absorbance 
Ad   Adenovirus 
ADEP   1-Amino-3,3-diethoxypropane 
ALD   Aldehyde 
Alexa-NHS  Alexa Fluor® 488 carboxylic acid, succinimidyl ester  
Alexa-SH Alexa Fluor® 488 carboxylic acid, succinimidyl ester modified 
with cysteamine 
AU   Absorbance unit 
BPEI  Branched polyethylenimine 25 kDa 
CAR  Coxsackie adenovirus receptor 
CEC   Cation exchange chromatography 
-CHO   Aldehyde group 
CMV   Cytomegalovirus 
Cya   Cysteamine 
DEAE   Diethylaminoethylene 
DLS   Dynamic light scattering 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMF   Dimethylformamid 
DNA   Deoxyribonucleic acid 
DTT   Dithiothreitol 
EDTA   Ethylenediaminetetraacetic acid 
EGF   Epidermal growth factor 
EGF-PEG-PEI25 EGF covalently linked to BPEI25 with a heterobifunctional  
3.4 kDa PEG spacer 
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EGFR   Epidermal growth factor receptor 
EPH   Electrophoresis 
ε   Extinction coefficient 
FCS Fetal calf serum 
HBG HEPES-buffered glucose 
HBS HEPES-buffered saline 
HBS 0.5x  HEPES-buffered glucose and HEPES-buffered   
   saline 1/1 (v/v) 
HEPES N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
HPLC High pressure liquid chromatography 
HR High resolution 
HZN Hydrazone 
LPEI  Linear polyethylenimine 22 kDa 
m-PEG Methoxy polyethyleneglycol 
MTT Methylthiazoletetrazolium 
Mw Molecular weight 
MWCO Molecular weight cut-off 
MQ De-ionized water (Millipore) 
NA   Nucleic acid  
NA 1,2  Numeric aperture of 1,2 
NaOAc  Sodium acetate  
NHS N-hydroxy succinimidyl ester 
N/P-ratio Molar ratio of PEI nitrogen to DNA phosphate 
OD Optical density 
OPSS Orthopyridyldisulfide 
PBS Phosphate-buffered saline 
PC Polycation 
pCMVLuc Plasmid encoding for luciferase under control of the CMV 
promoter/enhancer 
PEG Polyethylene glycol 
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PLL Poly-L-lysine 
RES   Reticulo Endothelial System 
RNA Ribonucleic acid 
RLU Relative light units 
RT Room temperature 
SEC Size exclusion chromatography 
Sephadex G25 Dextran-gel cross linked with epichlorhydrin, fractionation range 
0.1-5 kDa for dextrans 
Sepacryl S200 Allyldextran-gel cross linked by bisacrylamide, fractionation 
range 1-80 kDa for dextrans 
-SH Thiol group 
SHNH Succinimidyl-6-hydraziniumnicotinatehydrochloride 
SPA Succinimidylpropionic acid 
siRNA Small interfering RNA 
SS Disulfide 
SEC Size exclusion chromatography 
SD   Standard deviation 
TNBS   Trinitrobenzenesulfonic acid 
UF   Ultrafiltration 
UV/VIS  Ultraviolet/ visible light spectroscopy 
v   Volume 
w   Weight 
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6.2 Publications 
6.2.1 Original papers 
? Walker, G.F., Fella, C., Pelisek, J., Fahrmeir, J., Boeckle, S.,Ogris, M. and 
Wagner, E. (2005) “Toward Synthetic Viruses: Endosomal Triggered 
Deshielding of Targeted Polyplexes Greatly Enhances Gene Transfer In Vitro 
and In Vivo” Mol Ther 2005; 11(3):418-425 
 
? K.G. de Bruin, C. Fella, M. Ogris, E. Wagner, N. Ruthardt, C. Bräuchle (2008) 
“Dynamics of photoinduced endosomal release of polyplexes”, J Control 
Release 2008 
 
? C. Fella, Greg F. Walker, M. Ogris and E. Wagner (2008) “Amine-reactive 
pyridylhydrazone-based PEG N-hydroxysuccinimide esters for pH-reversible 
modification of targeted PEI polyplexes, Eur. J. Pharm. Sci 2008 
 
6.2.2 Poster presentations 
? Walker, G.F., Fella, C., Fahrmeir, J. and Wagner, E., 2005 “Bio-reversible 
PostPEGylation of targeted polyplexes enhances gene transfer in vitro” 
European Society Of Gene Therapy, Annual Meeting, Prague, Czech 
Republic 
 
? Bio-reversible Post-PEGylation of Targeted Polyplexes Enhances Gene 
Transfer in vitro Fella, C., Walker, G.F., Ogris M. and Wagner, E., CeNS 
Workshop, Venice International University , San Servolo, Venice, Italy 
 
6.2.3 Oral presentation 
Fella, C. (2006)  Development of novel non-viral vectors for tumour-targeted 
gene delivery – towards an ‘artificial virus’ Scientific colloquium, GIANT 
European Commission Funded Research , Munich, Germany  
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